{ "instance": { "cntb-20220630.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 158, "dts": { "calculationLink": { "local": [ "cntb-20220630_cal.xml" ] }, "definitionLink": { "local": [ "cntb-20220630_def.xml" ] }, "inline": { "local": [ "cntb-20220630.htm" ] }, "labelLink": { "local": [ "cntb-20220630_lab.xml" ] }, "presentationLink": { "local": [ "cntb-20220630_pre.xml" ] }, "schema": { "local": [ "cntb-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 542, "entityCount": 1, "hidden": { "http://www.connectbiopharm.com/20220630": 1, "http://xbrl.sec.gov/dei/2022": 4, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 2, "total": 7 }, "keyCustom": 78, "keyStandard": 199, "memberCustom": 28, "memberStandard": 24, "nsprefix": "cntb", "nsuri": "http://www.connectbiopharm.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Cover Page", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Critical Accounting Estimates and Judgements", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCriticalAccountingEstimatesAndJudgements", "shortName": "Critical Accounting Estimates and Judgements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Expenses by Nature", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNature", "shortName": "Expenses by Nature", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Employee Benefit Expenses", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureEmployeeBenefitExpenses", "shortName": "Employee Benefit Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Other Income", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncome1", "shortName": "Other Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Other (Losses)/Gains - Net", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNet", "shortName": "Other (Losses)/Gains - Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Income Taxes", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Loss Per Share", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLossPerShare1", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Property, Plant and Equipment", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Leases", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeases1", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Financial Assets at Fair Value Through Comprehensive Income", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncome", "shortName": "Financial Assets at Fair Value Through Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Unaudited Interim Condensed Consolidated Statements of Loss", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss", "shortName": "Unaudited Interim Condensed Consolidated Statements of Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Other non-current Assets", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssets", "shortName": "Other non-current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Other Receivables and Prepayments", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepayments", "shortName": "Other Receivables and Prepayments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Cash and Cash Equivalents", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalents1", "shortName": "Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Share Capital", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapital", "shortName": "Share Capital", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Share-Based Compensation", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Other Payables and Accruals", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccruals", "shortName": "Other Payables and Accruals", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Financial Instruments with Preferred Rights", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRights", "shortName": "Financial Instruments with Preferred Rights", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Cash Flow Information", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformation", "shortName": "Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Commitments", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Related Party Transactions", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss", "shortName": "Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "lang": null, "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Events After the Reporting Period", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureEventsAfterReportingPeriod", "shortName": "Events After the Reporting Period", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Fair Value Estimation (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationTables", "shortName": "Fair Value Estimation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Expenses by Nature (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureTables", "shortName": "Expenses by Nature (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Employee Benefit Expenses (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureEmployeeBenefitExpensesTables", "shortName": "Employee Benefit Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Other Income (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncomeTables", "shortName": "Other Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfOtherIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutScheduleOfOtherGainsLossesNetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Other (Losses)/Gains - Net (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetTables", "shortName": "Other (Losses)/Gains - Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfDetailedInformationAboutScheduleOfOtherGainsLossesNetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Loss Per Share (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Property, Plant and Equipment (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Leases (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Unaudited Interim Condensed Consolidated Balance Sheets", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets", "shortName": "Unaudited Interim Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "lang": null, "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "cntb:DisclosureOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:ScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Financial Assets at Fair Value Through Comprehensive Income (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeTables", "shortName": "Financial Assets at Fair Value Through Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "cntb:DisclosureOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:ScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Other non-current Assets (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsTables", "shortName": "Other non-current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Other Receivables and Prepayments (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsTables", "shortName": "Other Receivables and Prepayments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Cash and Cash Equivalents (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsTables", "shortName": "Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Share Capital (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalTables", "shortName": "Share Capital (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfScheduleOfOtherPayablesAndAccruals", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Other Payables and Accruals (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsTables", "shortName": "Other Payables and Accruals (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfScheduleOfOtherPayablesAndAccruals", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Financial Instruments with Preferred Rights (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsTables", "shortName": "Financial Instruments with Preferred Rights (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfCashUsedInOperationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Cash Flow Information (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationTables", "shortName": "Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:DisclosureOfCashUsedInOperationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Related Party Transactions (Tables)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_ddf29c39-3c9c-44aa-b44f-ac549e7c0911", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' (Deficit)/Equity", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity", "shortName": "Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' (Deficit)/Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_41706d9e-f4d8-44e2-b37f-4bbb709eeb08", "decimals": "-3", "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - General Information, Reorganization and Basis of Presentation - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "shortName": "General Information, Reorganization and Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "cntb:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-8", "lang": null, "name": "ifrs-full:AccumulatedOtherComprehensiveIncome", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "U_RmbPerUsd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "U_RmbPerUsd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_87765318-1de4-4449-a976-04784ab3a70f", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Fair Value Estimation - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationAdditionalInformationDetails", "shortName": "Fair Value Estimation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_87765318-1de4-4449-a976-04784ab3a70f", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Fair Value Estimation - Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails", "shortName": "Fair Value Estimation - Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_d32de295-d6dd-4533-b1e0-810a87e3cd9a", "decimals": "-3", "lang": null, "name": "ifrs-full:CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:SummaryOfChangesInFinancialInstrumentsOfShortTermAndLongTermInvestments", "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "cntb:PurchaseOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Fair Value Estimation - Summary of Changes in Financial Instruments of Short-term and Long-term Investments (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInFinancialInstrumentsOfShorttermAndLongtermInvestmentsDetails", "shortName": "Fair Value Estimation - Summary of Changes in Financial Instruments of Short-term and Long-term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:SummaryOfChangesInFinancialInstrumentsOfShortTermAndLongTermInvestments", "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "lang": null, "name": "cntb:AccruedInterestOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesTextBlock", "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_b98e47b4-bf8f-466a-a054-1b982f8aad53", "decimals": "-3", "first": true, "lang": null, "name": "cntb:FinancialAssetsLiabilitiesAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Fair Value Estimation - Summary of Changes in Level 3 Instruments of Short-term Investment (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails", "shortName": "Fair Value Estimation - Summary of Changes in Level 3 Instruments of Short-term Investment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesTextBlock", "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_b98e47b4-bf8f-466a-a054-1b982f8aad53", "decimals": "-3", "first": true, "lang": null, "name": "cntb:FinancialAssetsLiabilitiesAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ClinicalTrialsRelatedExpenses", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Expenses by Nature - Summary of Expenses by Nature (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails", "shortName": "Expenses by Nature - Summary of Expenses by Nature (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ClinicalTrialsRelatedExpenses", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Employee Benefit Expenses - Schedule of Employee Benefit Expenses (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails", "shortName": "Employee Benefit Expenses - Schedule of Employee Benefit Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesExplanatory", "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:EmployeeBenefitsExpense", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Employee Benefit Expenses - Schedule of Employee Benefit Expenses Included in Consolidated Statements of Loss (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "shortName": "Employee Benefit Expenses - Schedule of Employee Benefit Expenses Included in Consolidated Statements of Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_9e92e3db-7022-41a9-a569-9d5f631f7643", "decimals": "-3", "lang": null, "name": "ifrs-full:EmployeeBenefitsExpense", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfOtherIncomeExplanatory", "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Other Income - Summary of Other Income (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncomeSummaryOfOtherIncomeDetails", "shortName": "Other Income - Summary of Other Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfOtherIncomeExplanatory", "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfCashUsedInOperationsExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashFlowsFromUsedInOperations", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Unaudited Interim Condensed Consolidated Statements of Cash Flows", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows", "shortName": "Unaudited Interim Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "lang": null, "name": "ifrs-full:InterestReceivedClassifiedAsOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_e2f6a9d2-9a75-47fd-aecb-6f6df81b6339", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:RevenueFromGovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Other Income - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncomeAdditionalInformationDetails", "shortName": "Other Income - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_e2f6a9d2-9a75-47fd-aecb-6f6df81b6339", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:RevenueFromGovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Other (Losses)/Gains - Net - Schedule of Other (Losses)/Gains - Net (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetDetails", "shortName": "Other (Losses)/Gains - Net - Schedule of Other (Losses)/Gains - Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_3540a187-3fb9-4880-9a36-da4e2e705616", "decimals": "-5", "first": true, "lang": null, "name": "cntb:OtherNonOperatingIncomesExpenses", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Other (Losses)/Gains - Net - Schedule of Other (Losses)/Gains - Net (Parenthetical) (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetParentheticalDetails", "shortName": "Other (Losses)/Gains - Net - Schedule of Other (Losses)/Gains - Net (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "cntb:DisclosureOfOtherIncomeLossesNetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-5", "lang": null, "name": "cntb:LossesRecoveredFromCyberInsurance", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IncomeTaxExpenseContinuingOperations", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Income taxes - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "lang": null, "name": "cntb:UnrecognizedUncertainTaxPositions", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Loss Per Share - Schedule of Net Basic Loss Per Share (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLossPerShareScheduleOfNetBasicLossPerShareDetails", "shortName": "Loss Per Share - Schedule of Net Basic Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_e2f6a9d2-9a75-47fd-aecb-6f6df81b6339", "decimals": "0", "lang": null, "name": "ifrs-full:WeightedAverageShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "shortName": "Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "lang": null, "name": "ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_87765318-1de4-4449-a976-04784ab3a70f", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails", "shortName": "Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "lang": null, "name": "ifrs-full:AdditionsToRightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatoryTextBlock", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentLeaseLiabilities", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails", "shortName": "Leases - Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatoryTextBlock", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "lang": null, "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Leases - Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails", "shortName": "Leases - Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:CashOutflowForLeases", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:CashOutflowForLeases", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - General Information, Reorganization and Basis of Presentation", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentation", "shortName": "General Information, Reorganization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:ScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "div", "cntb:DisclosureOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Financial Assets at Fair Value Through Comprehensive Income - Schedule of Financial Assets at Fair Value Through Comprehensive Income of Debt Securities (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeOfDebtSecurit", "shortName": "Financial Assets at Fair Value Through Comprehensive Income - Schedule of Financial Assets at Fair Value Through Comprehensive Income of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:ScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "div", "cntb:DisclosureOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:ScheduleOfDebtInvestmentsRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatory", "div", "cntb:DisclosureOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Financial Assets at Fair Value Through Comprehensive Income - Schedule of Debt Investments Recognized in Profit or Loss and Other Comprehensive Income Explanatory (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfDebtInvestmentsRecognizedInProfitOrLossAndOtherComprehensiveIncom", "shortName": "Financial Assets at Fair Value Through Comprehensive Income - Schedule of Debt Investments Recognized in Profit or Loss and Other Comprehensive Income Explanatory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:ScheduleOfDebtInvestmentsRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatory", "div", "cntb:DisclosureOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentValueAddedTaxReceivables", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100800 - Disclosure - Other non-current Assets - Schedule of Other Non-current Assets (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails", "shortName": "Other non-current Assets - Schedule of Other Non-current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentValueAddedTaxReceivables", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_d09bf2ba-2ba4-45a6-9aea-36a0b98590df", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:NoncurrentPrepayments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100810 - Disclosure - Other non-current Assets - Schedule of Other Non-current Assets (Parenthetical) (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "shortName": "Other non-current Assets - Schedule of Other Non-current Assets (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "cntb:DisclosureOfOtherNonCurrentAssetExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_d09bf2ba-2ba4-45a6-9aea-36a0b98590df", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:NoncurrentPrepayments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Prepayments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100820 - Disclosure - Other Receivables and Prepayments - Schedule of Other Receivables and Prepayments (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails", "shortName": "Other Receivables and Prepayments - Schedule of Other Receivables and Prepayments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Prepayments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "div", "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:LiabilityInsuranceAmortizedPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100830 - Disclosure - Other Receivables and Prepayments - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherReceivablesAndPrepaymentsAdditionalInformationDetails", "shortName": "Other Receivables and Prepayments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "cntb:DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "div", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "cntb:LiabilityInsuranceAmortizedPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100840 - Disclosure - Cash and Cash Equivalents - Schedule of Cash And Cash Equivalents (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "shortName": "Cash and Cash Equivalents - Schedule of Cash And Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100850 - Disclosure - Cash and Cash Equivalents - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "shortName": "Cash and Cash Equivalents - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_bf4ec804-a311-4733-a0df-b7832aa32a6b", "decimals": "-5", "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_8e2d0c8b-d187-4af2-807c-7b6f2fbef2b5", "decimals": "2", "first": true, "lang": null, "name": "cntb:ConversionOfOrdinarySharesConverted", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100860 - Disclosure - Share Capital - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "shortName": "Share Capital - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_8e2d0c8b-d187-4af2-807c-7b6f2fbef2b5", "decimals": "2", "first": true, "lang": null, "name": "cntb:ConversionOfOrdinarySharesConverted", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_87765318-1de4-4449-a976-04784ab3a70f", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100870 - Disclosure - Share Capital - Schedule of Share Capital and Share Premium (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "shortName": "Share Capital - Schedule of Share Capital and Share Premium (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_9218c4ab-ff89-41aa-8784-478ee0ca69f3", "decimals": "-3", "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "cntb:SharesReservedForFutureIssuanceUnderTwoThousandNineteenStockIncentivePlan", "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "INF", "first": true, "lang": null, "name": "cntb:SharesReservedForFutureIssuanceUnderTwoThousandNineteenStockIncentivePlan", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100880 - Disclosure - Share-Based Compensation - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "shortName": "Share-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_87765318-1de4-4449-a976-04784ab3a70f", "decimals": "INF", "lang": null, "name": "cntb:SharesReservedForFutureIssuanceUnderTwoThousandNineteenStockIncentivePlan", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_87765318-1de4-4449-a976-04784ab3a70f", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100890 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails", "shortName": "Share-Based Compensation - Summary of Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_5a7cbd52-2c0c-4e78-9892-0d0902ccb33d", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100900 - Disclosure - Share-Based Compensation - Summary of Key Assumptions for Options Granted (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "shortName": "Share-Based Compensation - Summary of Key Assumptions for Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_5a7cbd52-2c0c-4e78-9892-0d0902ccb33d", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "cntb:ForfeitureRateShareOptionsGranted", "span", "p", "ix:continuation", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_0c48ffac-3a20-4f0d-8f1d-0db1e1b56225", "decimals": "3", "first": true, "lang": null, "name": "cntb:ForfeitureRateShareOptionsGranted", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100910 - Disclosure - Share-Based Compensation - Summary of Key Assumptions for Options Granted (Parenthetical) (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "shortName": "Share-Based Compensation - Summary of Key Assumptions for Options Granted (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R84": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100920 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expenses (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails", "shortName": "Share-Based Compensation - Summary of Share-Based Compensation Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfScheduleOfOtherPayablesAndAccruals", "div", "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ConstructionPayables", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100930 - Disclosure - Other Payables and Accruals - Schedule of Other Payables and Accruals (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails", "shortName": "Other Payables and Accruals - Schedule of Other Payables and Accruals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfScheduleOfOtherPayablesAndAccruals", "div", "cntb:DisclosureOfOtherPayablesAndAccrualsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "first": true, "lang": null, "name": "cntb:ConstructionPayables", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100940 - Disclosure - Financial Instruments with Preferred Rights - Summary of Series of Financings by Issuing Preferred Shares (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails", "shortName": "Financial Instruments with Preferred Rights - Summary of Series of Financings by Issuing Preferred Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "-3", "lang": null, "name": "cntb:PreferredSharesSubscriptionConsideration", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100950 - Disclosure - Financial Instruments with Preferred Rights - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "shortName": "Financial Instruments with Preferred Rights - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_2aa06b00-f05f-4bf0-8e34-87710bd7192a", "decimals": "INF", "lang": null, "name": "cntb:ConversionFromPreferredSharesToOrdinarySharesAfterShareConsolidation", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100960 - Disclosure - Financial Instruments with Preferred Rights - Movements of Financial Instruments with Preferred Rights (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails", "shortName": "Financial Instruments with Preferred Rights - Movements of Financial Instruments with Preferred Rights (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_41ad1d7a-d23c-4dd9-b0d8-f8c2c4d01d89", "decimals": "-3", "lang": null, "name": "ifrs-full:AggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_734db3a8-7dfe-431a-9e2a-b99264ab39fa", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:SignificantUnobservableInputLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100970 - Disclosure - Financial Instruments with Preferred Rights - Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "shortName": "Financial Instruments with Preferred Rights - Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "cntb:DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_734db3a8-7dfe-431a-9e2a-b99264ab39fa", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:SignificantUnobservableInputLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Fair Value Estimation", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimation", "shortName": "Fair Value Estimation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfCashUsedInOperationsExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100980 - Disclosure - Cash Flow Information - Summary of Cash Used in Operations (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails", "shortName": "Cash Flow Information - Summary of Cash Used in Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cntb:DisclosureOfCashUsedInOperationsExplanatory", "div", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "lang": null, "name": "cntb:AdjustmentsForInvestmentIncomeFromWealthManagementProducts", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ContractualCapitalCommitments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100990 - Disclosure - Commitments - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "shortName": "Commitments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_924a7ce2-8b39-4ca0-9f51-560d7c639dfd", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ContractualCapitalCommitments", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_f32c5072-931e-418b-bf99-a94d85c9444b", "decimals": "INF", "first": true, "lang": null, "name": "cntb:NumberOfSharesSurrenderedAndCancelled", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101000 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_f32c5072-931e-418b-bf99-a94d85c9444b", "decimals": "INF", "lang": null, "name": "cntb:SharesSurrenderedAndCancelledConsiderationValue", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101010 - Disclosure - Related Party Transactions - Summary of Key Management Personnel Compensation (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails", "shortName": "Related Party Transactions - Summary of Key Management Personnel Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-5", "first": true, "lang": null, "name": "cntb:KeyManagementPersonnelCompensationShareBasedPaymentFromForfeitureOfUnvestedStockOptions", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101020 - Disclosure - Related Party Transactions - Summary of Key Management Personnel Compensation (Parenthetical) (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationParentheticalDetails", "shortName": "Related Party Transactions - Summary of Key Management Personnel Compensation (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "-5", "first": true, "lang": null, "name": "cntb:KeyManagementPersonnelCompensationShareBasedPaymentFromForfeitureOfUnvestedStockOptions", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_adb37fdb-3cb7-47ee-81f3-8ef38a460311", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101030 - Disclosure - Events After the Reporting Period - Additional Information (Details)", "role": "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails", "shortName": "Events After the Reporting Period - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "body", "html" ], "baseRef": "cntb-20220630.htm", "contextRef": "C_10e9eb3c-3fce-46b7-a9e0-7fc307a0aaea", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "cntb_AccruedInterestOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued interest of Financial Assets at Fair Value through Other Comprehensive Income", "label": "Accrued interest of Financial Assets at Fair Value through Other Comprehensive Income", "terseLabel": "Accrued interest (net of coupon interest received)" } } }, "localname": "AccruedInterestOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInFinancialInstrumentsOfShorttermAndLongtermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AccruedProfessionalServiceFee": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails": { "order": 0.0, "parentTag": "cntb_OtherPayablesAndAccruals", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued professional service fee.", "label": "Accrued Professional Service Fee", "terseLabel": "Accrued professional service fee" } } }, "localname": "AccruedProfessionalServiceFee", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AdditionalSharesAvailableForIssuanceUnderThePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional shares available for issuance under the plan.", "label": "Additional Shares Available for Issuance Under the Plan", "terseLabel": "Additional shares available for issuance under the plan" } } }, "localname": "AdditionalSharesAvailableForIssuanceUnderThePlan", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_AdjustmentsForDepreciationOfPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation of property, plant and equipment.", "label": "Adjustments For Depreciation Of Property Plant And Equipment", "terseLabel": "Depreciation of property, plant and equipment" } } }, "localname": "AdjustmentsForDepreciationOfPropertyPlantAndEquipment", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AdjustmentsForDepreciationOfRightsOfUseAssets": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation of rights of use assets.", "label": "Adjustments For Depreciation Of Rights Of Use Assets", "terseLabel": "Depreciation of rights-of-use assets" } } }, "localname": "AdjustmentsForDepreciationOfRightsOfUseAssets", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AdjustmentsForInvestmentIncomeFromInvestmentsAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments for investment income from investments at fair value through other comprehensive income.", "label": "Adjustments For Investment Income From Investments at Fair Value Through Other Comprehensive Income", "negatedLabel": "Investment income from investments at fair value through other comprehensive income" } } }, "localname": "AdjustmentsForInvestmentIncomeFromInvestmentsAtFairValueThroughOtherComprehensiveIncome", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AdjustmentsForInvestmentIncomeFromWealthManagementProducts": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments for investment income from wealth management products.", "label": "Adjustments For Investment Income From Wealth Management Products", "negatedLabel": "Investment income from investments at fair value through profit and loss and wealth management products", "terseLabel": "-Investment income from wealth management products" } } }, "localname": "AdjustmentsForInvestmentIncomeFromWealthManagementProducts", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_AdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Administrative expenses.", "label": "Administrative Expenses [Member]", "terseLabel": "Administrative Expenses" } } }, "localname": "AdministrativeExpensesMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "cntb_BasicAndDilutedEarningsLossPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basic and diluted earnings loss per share.", "label": "Basic And Diluted Earnings Loss Per Share", "terseLabel": "Basic and diluted" } } }, "localname": "BasicAndDilutedEarningsLossPerShare", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "perShareItemType" }, "cntb_CashAndCashEquivalentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent.", "label": "Cash And Cash Equivalent [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "cntb_CashCashEquivalentAndShortTermInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalent, and short-term investments.", "label": "Cash, cash equivalent, and short-term investments", "terseLabel": "Cash, cash equivalents, and short-term investments" } } }, "localname": "CashCashEquivalentAndShortTermInvestments", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_ChangesInOperatingAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Changes in operating assets and liabilities.", "label": "Changes In Operating Assets And Liabilities [Abstract]", "terseLabel": "Changes in working capital" } } }, "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "stringItemType" }, "cntb_ClinicalTrialsRelatedExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 0.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Clinical trials related expenses.", "label": "Clinical Trials Related Expenses", "terseLabel": "Clinical trials related expenses" } } }, "localname": "ClinicalTrialsRelatedExpenses", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "cntb_CoFoundersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Co-Founders.", "label": "Co Founders [Member]", "terseLabel": "Co-Founders" } } }, "localname": "CoFoundersMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_ConnectUSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Connect US.", "label": "Connect U S [Member]", "terseLabel": "Connect Biopharm LLC" } } }, "localname": "ConnectUSMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_ConsiderationForSharesSurrenderedRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Consideration for shares surrendered related party.", "label": "Consideration For Shares Surrendered Related Party", "terseLabel": "Consideration for ordinary shares surrendered, related party" } } }, "localname": "ConsiderationForSharesSurrenderedRelatedParty", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_ConstructionPayables": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails": { "order": 2.0, "parentTag": "cntb_OtherPayablesAndAccruals", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Construction payables.", "label": "Construction Payables", "terseLabel": "Construction payables" } } }, "localname": "ConstructionPayables", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_ContributionsByAndDistributionsToOwnersOfParent": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contributions by and distributions to owners of parent.", "label": "Contributions By And Distributions To Owners Of Parent", "totalLabel": "Total Transactions with owners" } } }, "localname": "ContributionsByAndDistributionsToOwnersOfParent", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_ConversionFromPreferredSharesToOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion from preferred shares to ordinary shares.", "label": "Conversion from Preferred Shares to Ordinary Shares", "terseLabel": "Conversion from preferred shares to ordinary shares, shares" } } }, "localname": "ConversionFromPreferredSharesToOrdinaryShares", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "cntb_ConversionFromPreferredSharesToOrdinarySharesAfterShareConsolidation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion from preferred shares to ordinary shares after share consolidation.", "label": "Conversion From Preferred Shares To Ordinary Shares After Share Consolidation", "terseLabel": "Conversion from preferred shares to ordinary shares after share consolidation" } } }, "localname": "ConversionFromPreferredSharesToOrdinarySharesAfterShareConsolidation", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_ConversionOfOrdinarySharesConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of ordinary shares converted.", "label": "Conversion Of Ordinary Shares Converted", "terseLabel": "Ordinary shares consolidation" } } }, "localname": "ConversionOfOrdinarySharesConverted", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_CriticalAccountingEstimatesAndJudgementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Critical accounting estimates and judgements.", "label": "Critical Accounting Estimates And Judgements [Abstract]" } } }, "localname": "CriticalAccountingEstimatesAndJudgementsAbstract", "nsuri": "http://www.connectbiopharm.com/20220630", "xbrltype": "stringItemType" }, "cntb_Deposit": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails": { "order": 1.0, "parentTag": "cntb_OtherReceivablesAndPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits.", "label": "Deposit", "terseLabel": "Deposits" } } }, "localname": "Deposit", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for basis of preparation explanatory.", "label": "Description Of Accounting Policy For Basis Of Preparation Explanatory", "terseLabel": "Basis of Presentation" } } }, "localname": "DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cntb_DescriptionOfAccountingPolicyForInvestmentAndOtherFinancialAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for investment and other financial assets explanatory.", "label": "Description Of Accounting Policy For Investment And Other Financial Assets Explanatory", "terseLabel": "Investments and other financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForInvestmentAndOtherFinancialAssetsExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cntb_DescriptionOfAccountingPolicyForNewAndAmendedStandardsAndNotYetAdoptedInterpretationsAdoptedExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for New and amended standards and not yet adopted interpretations adopted explanatory.", "label": "Description of accounting policy for New and amended standards and not yet adopted interpretations adopted explanatory", "terseLabel": "New and amended standards and interpretations adopted and not yet adopted by the Group" } } }, "localname": "DescriptionOfAccountingPolicyForNewAndAmendedStandardsAndNotYetAdoptedInterpretationsAdoptedExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cntb_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for principles of consolidation explanatory.", "label": "Description Of Accounting Policy For Principles Of Consolidation Explanatory", "terseLabel": "Principles of consolidation" } } }, "localname": "DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cntb_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetAdoptedExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for standards issued but not yet adopted explanatory.", "label": "Description Of Accounting Policy For Standards Issued But Not Yet Adopted Explanatory", "terseLabel": "New and amended standards and interpretations not yet adopted by the Group" } } }, "localname": "DescriptionOfAccountingPolicyForStandardsIssuedButNotYetAdoptedExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash flow information.", "label": "Disclosure Of Cash Flow Information [Abstract]" } } }, "localname": "DisclosureOfCashFlowInformationAbstract", "nsuri": "http://www.connectbiopharm.com/20220630", "xbrltype": "stringItemType" }, "cntb_DisclosureOfCashUsedInOperationsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash used in operations.", "label": "Disclosure Of Cash Used In Operations Explanatory", "terseLabel": "Summary of Cash Used in Operations" } } }, "localname": "DisclosureOfCashUsedInOperationsExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about employee benefit expenses.", "label": "Disclosure Of Detailed Information About Employee Benefit Expenses Explanatory", "terseLabel": "Schedule of Employee Benefit Expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitExpensesExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureEmployeeBenefitExpensesTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfDetailedInformationAboutFinanceIncomeCostNet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about finance income/(cost) net.", "label": "Disclosure of Detailed Information about Finance Income/(Cost) Net", "terseLabel": "Summary of Finance Income/(Cost) Net" } } }, "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeCostNet", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinanceIncomecostNetTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about schedule of income tax expense reconciliation.", "label": "Disclosure Of Detailed Information About Schedule Of Income Tax Expense Reconciliation Explanatory", "terseLabel": "Schedule of Reconciliation between Actual Tax Charge and Amount Calculated based on Statutory Income Tax Rate" } } }, "localname": "DisclosureOfDetailedInformationAboutScheduleOfIncomeTaxExpenseReconciliationExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfDetailedInformationAboutScheduleOfOtherGainsLossesNetExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about schedule of other gains/(losses) - net.", "label": "Disclosure Of Detailed Information About Schedule Of Other Gains Losses Net Explanatory", "terseLabel": "Schedule of Other (Losses)/Gains - Net" } } }, "localname": "DisclosureOfDetailedInformationAboutScheduleOfOtherGainsLossesNetExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of financial assets at fair value through comprehensive income.", "label": "Disclosure of Financial Assets at Fair Value Through Comprehensive Income Explanatory", "terseLabel": "Financial Assets at Fair Value Through Comprehensive Income" } } }, "localname": "DisclosureOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of financial instruments with preferred rights explanatory.", "label": "Disclosure Of Financial Instruments With Preferred Rights Explanatory", "terseLabel": "Financial Instruments with Preferred Rights" } } }, "localname": "DisclosureOfFinancialInstrumentsWithPreferredRightsExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRights" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of general information, reorganization and basis of presentation.", "label": "Disclosure Of General Information Reorganization And Basis Of Presentation [Abstract]" } } }, "localname": "DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationAbstract", "nsuri": "http://www.connectbiopharm.com/20220630", "xbrltype": "stringItemType" }, "cntb_DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of general information, reorganization and basis of presentation.", "label": "Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]", "terseLabel": "Disclosure Of General Information Reorganization And Basis Of Presentation [Line Items]" } } }, "localname": "DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationLineItems", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of general information, reorganization and basis of presentation.", "label": "Disclosure Of General Information Reorganization And Basis Of Presentation [Table]", "terseLabel": "Disclosure Of General Information Reorganization And Basis Of Presentation [Table]" } } }, "localname": "DisclosureOfGeneralInformationReorganizationAndBasisOfPresentationTable", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfIncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of income taxes.", "label": "Disclosure Of Income Taxes [Line Items]", "terseLabel": "Disclosure Of Income Taxes [Line Items]" } } }, "localname": "DisclosureOfIncomeTaxesLineItems", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfIncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of income taxes.", "label": "Disclosure Of Income Taxes [Table]", "terseLabel": "Disclosure Of Income Taxes [Table]" } } }, "localname": "DisclosureOfIncomeTaxesTable", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cntb_DisclosureOfNonCashInvestingAndFinancingActivitiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of non cash investing and financing activities explanatory.", "label": "Disclosure Of Non Cash Investing and Financing Activities Explanatory", "terseLabel": "Summary of Non-cash Investing and Financing Activities" } } }, "localname": "DisclosureOfNonCashInvestingAndFinancingActivitiesExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfOtherIncomeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other income explanatory.", "label": "Disclosure of Other Income Explanatory", "terseLabel": "Summary of Other income" } } }, "localname": "DisclosureOfOtherIncomeExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncomeTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfOtherIncomeLossesNetExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Other income (losses) net.", "label": "Disclosure of Other income (losses) net explanatory", "terseLabel": "Other (Losses)/Gains - Net" } } }, "localname": "DisclosureOfOtherIncomeLossesNetExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNet" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfOtherNonCurrentAssetExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other non-current assets explanatory.", "label": "Disclosure Of Other Non Current Asset Explanatory", "verboseLabel": "Other non-current Assets" } } }, "localname": "DisclosureOfOtherNonCurrentAssetExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssets" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfOtherPayablesAndAccrualsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of other payables and accruals explanatory.", "label": "Disclosure Of Other Payables and Accruals Explanatory", "terseLabel": "Other Payables and Accruals" } } }, "localname": "DisclosureOfOtherPayablesAndAccrualsExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccruals" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfPropertyPlantAndEquipmentUsefulLifeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of property, plant and equipment useful life explanatory", "label": "Summary of property, plant and equipment useful life" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentUsefulLifeExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfQuantitativeInformationAboutAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of quantitative information about amounts recognized in consolidated statements of loss in addition to depreciation explanatory.", "label": "Disclosure of Quantitative Information About Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation Explanatory [Text Block]", "terseLabel": "Schedule of Amounts Recognized in Consolidated Statements of Loss in Addition to Depreciation" } } }, "localname": "DisclosureOfQuantitativeInformationAboutAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationExplanatoryTextBlock", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of quantitative information about lease liabilities explanatory.", "label": "Disclosure of Quantitative Information about Lease Liabilities Explanatory [Text Block]", "terseLabel": "Schedule of Amounts Recognized in Consolidated Balance Sheets as Lease Liability" } } }, "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatoryTextBlock", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of restricted net assets and parent company condensed financial information.", "label": "Disclosure Of Restricted Net Assets And Parent Company Condensed Financial Information Explanatory", "terseLabel": "Restricted Net Assets and Parent Company Only Condensed Financial Information" } } }, "localname": "DisclosureOfRestrictedNetAssetsAndParentCompanyCondensedFinancialInformationExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRestrictedNetAssetsAndParentCompanyOnlyCondensedFinancialInformation" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfScheduleOfOtherPayablesAndAccruals": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of schedule of other payables and accruals.", "label": "Disclosure Of Schedule Of Other Payables And Accruals", "terseLabel": "Schedule of Other Payables and Accruals" } } }, "localname": "DisclosureOfScheduleOfOtherPayablesAndAccruals", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfScheduleOfOtherReceivablesAndPrepayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of schedule of other receivables and prepayments.", "label": "Disclosure Of Schedule Of Other Receivables And Prepayments", "terseLabel": "Schedule of Other Receivables and Prepayments" } } }, "localname": "DisclosureOfScheduleOfOtherReceivablesAndPrepayments", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities.", "label": "Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities [Text block]", "terseLabel": "Summary of Changes in Level 3 Instruments of Short-term Investment" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesTextBlock", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of summary of cash and cash equivalents explanatory.", "label": "Disclosure of Summary of Cash and Cash Equivalents Explanatory", "terseLabel": "Summary of Cash and Cash Equivalents" } } }, "localname": "DisclosureOfSummaryOfCashAndCashEquivalentsExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "cntb_DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of summary of financial instruments with preferred rights.", "label": "Disclosure Of Summary of Financial Instruments With Preferred Rights Explanatory", "terseLabel": "Summary of Series of Financings by Issuing Preferred Shares" } } }, "localname": "DisclosureOfSummaryOfFinancialInstrumentsWithPreferredRightsExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsTables" ], "xbrltype": "textBlockItemType" }, "cntb_DiscountAccretedOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discount Accreted of Financial Assets at Fair Value through Other Comprehensive Income", "label": "Discount Accreted of Financial Assets at Fair Value through Other Comprehensive Income", "terseLabel": "Discount Accreted" } } }, "localname": "DiscountAccretedOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInFinancialInstrumentsOfShorttermAndLongtermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_DiscountRateForLackOfMarketabilityMeasurementInputMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discount rate for lack of marketability, measurement input.", "label": "Discount Rate For Lack Of Marketability Measurement Input [Member]", "terseLabel": "Discount for Lack of Marketability" } } }, "localname": "DiscountRateForLackOfMarketabilityMeasurementInputMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "cntb_EmployeeSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Share Purchase Plan.", "label": "Employee Share Purchase Plan [Member]", "terseLabel": "ESPP" } } }, "localname": "EmployeeSharePurchasePlanMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "domainItemType" }, "cntb_EquipmentAndImprovementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment and improvement.", "label": "Equipment And Improvement [Member]", "terseLabel": "Equipment and Improvement" } } }, "localname": "EquipmentAndImprovementMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_ExpectedEarlyExerciseMultiple": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected early exercise multiple.", "label": "Expected Early Exercise Multiple", "terseLabel": "Expected early exercise multiple" } } }, "localname": "ExpectedEarlyExerciseMultiple", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "pureItemType" }, "cntb_FinancialAssetsLiabilitiesAtFairValueThroughProfitOrLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial assets (liabilities) at fair value through profit or loss.", "label": "Financial Assets Liabilities At Fair Value Through Profit Or Loss", "periodEndLabel": "Closing balance", "periodStartLabel": "Opening balance", "terseLabel": "Wealth management products" } } }, "localname": "FinancialAssetsLiabilitiesAtFairValueThroughProfitOrLoss", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "cntb_FinancialInstrumentsWithPreferredRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instruments with preferred rights.", "label": "Financial Instruments With Preferred Rights [Member]", "terseLabel": "Financial Instruments with Preferred Rights" } } }, "localname": "FinancialInstrumentsWithPreferredRightsMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "cntb_ForfeitureRateShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Forfeiture rate, share options granted.", "label": "Forfeiture Rate Share Options Granted", "terseLabel": "Forfeiture rate", "verboseLabel": "Forfeiture rate for executives and directors, and all other employees" } } }, "localname": "ForfeitureRateShareOptionsGranted", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails" ], "xbrltype": "percentItemType" }, "cntb_GainsLossesOnConversionToOrdinarySharesUponInitialPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gains losses on conversion to ordinary shares upon initial public offering.", "label": "Gains Losses on Conversion to Ordinary Shares Upon Initial Public Offering", "negatedLabel": "Converted to ordinary shares upon IPO" } } }, "localname": "GainsLossesOnConversionToOrdinarySharesUponInitialPublicOffering", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_HousingFunds": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": 4.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Housing funds.", "label": "Housing Funds", "terseLabel": "Housing funds" } } }, "localname": "HousingFunds", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cntb_IncreaseDecreaseInNumberOfOrdinarySharesIssuedToCoFounders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase decrease in number of ordinary shares issued to co-founders.", "label": "Increase Decrease In Number Of Ordinary Shares Issued to Co-founders", "terseLabel": "Issuance of shares to Co-founders, shares", "verboseLabel": "Issuance of shares to Co-Founders, shares" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssuedToCoFounders", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "cntb_IncreaseDecreaseInValueOfOrdinarySharesIssued": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 0.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "increase decrease in value of ordinary shares issued.", "label": "Increase Decrease in Value of Ordinary Shares Issued", "verboseLabel": "Issuance of Ordinary Shares" } } }, "localname": "IncreaseDecreaseInValueOfOrdinarySharesIssued", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_IncreaseDecreaseInValueOfOrdinarySharesIssuedToCoFounders": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 5.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in value of ordinary shares issued to co-founders.", "label": "Increase Decrease In Value Of Ordinary Shares Issued To Co-founders", "terseLabel": "Issuance of shares to Co-founders", "verboseLabel": "Issuance of shares to Co-Founders" } } }, "localname": "IncreaseDecreaseInValueOfOrdinarySharesIssuedToCoFounders", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_InitialPublicOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering Price", "label": "Initial Public Offering Price", "terseLabel": "Initial public offering price" } } }, "localname": "InitialPublicOfferingPrice", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "cntb_InternalRateOfReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internal Rate of Return", "label": "Internal Rate of Return", "terseLabel": "Internal rate of return" } } }, "localname": "InternalRateOfReturn", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_IssuanceOfTreasuryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of treasury shares.", "label": "Issuance Of Treasury Shares", "terseLabel": "Issuance of treasury shares, shares" } } }, "localname": "IssuanceOfTreasuryShares", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "cntb_IssuanceOfValueOfTreasuryShares": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 6.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of value of treasury shares.", "label": "Issuance Of Value Of Treasury Shares", "terseLabel": "Issuance of treasury shares" } } }, "localname": "IssuanceOfValueOfTreasuryShares", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_IssuedCapitalAndSharePremiumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued capital and share premium.", "label": "Issued Capital And Share Premium [Member]", "terseLabel": "Share Capital and Share Premium" } } }, "localname": "IssuedCapitalAndSharePremiumMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "domainItemType" }, "cntb_KeyManagementPersonnelCompensationShareBasedPaymentFromForfeitureOfUnvestedStockOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation, share-based payment from forfeiture of unvested stock options.", "label": "Key Management Personnel Compensation Share Based Payment From Forfeiture Of Unvested Stock Options", "terseLabel": "Share-based compensation expense from forfeiture of unvested stock options" } } }, "localname": "KeyManagementPersonnelCompensationShareBasedPaymentFromForfeitureOfUnvestedStockOptions", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "cntb_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cntb_LandUseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Land use rights.", "label": "Land use Rights [Member]", "terseLabel": "Land use Rights" } } }, "localname": "LandUseRightsMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "domainItemType" }, "cntb_LiabilityInsuranceAmortizedPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability insurance amortized period", "label": "Liability Insurance Amortized Period", "terseLabel": "Amortized period" } } }, "localname": "LiabilityInsuranceAmortizedPeriod", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherReceivablesAndPrepaymentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cntb_ListedBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Listed bonds.", "label": "Listed Bonds Member", "terseLabel": "Listed Bonds" } } }, "localname": "ListedBondsMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeOfDebtSecurit" ], "xbrltype": "domainItemType" }, "cntb_LossesPartiallyRecoveredFromCyberInsurance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Losses partially recovered from cyber insurance.", "label": "Losses Partially Recovered from Cyber Insurance", "terseLabel": "Losses partially recovered from cyber insurance" } } }, "localname": "LossesPartiallyRecoveredFromCyberInsurance", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "cntb_LossesRecoveredFromCyberInsurance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Losses recovered from cyber insurance.", "label": "Losses Recovered From Cyber Insurance", "terseLabel": "Losses recovered from cyber insurance" } } }, "localname": "LossesRecoveredFromCyberInsurance", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "cntb_NonCurrentDeferredRevenue": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non current deferred revenue.", "label": "Non Current Deferred Revenue", "terseLabel": "Deferred income" } } }, "localname": "NonCurrentDeferredRevenue", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cntb_NumberOfPurchasesMadeInTheOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of purchases made in the offering.", "label": "Number of Purchases Made in the Offering", "terseLabel": "Number of purchases made" } } }, "localname": "NumberOfPurchasesMadeInTheOffering", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "cntb_NumberOfSegments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of segments.", "label": "Number Of Segments", "terseLabel": "Number of segments" } } }, "localname": "NumberOfSegments", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cntb_NumberOfSharesIssuedAtConsolidation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued at consolidation.", "label": "Number of shares issued at consolidation" } } }, "localname": "NumberOfSharesIssuedAtConsolidation", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_NumberOfSharesRepresentedByOneDepositaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares represented by one depositary shares.", "label": "Number of Shares Represented by One Depositary Shares", "terseLabel": "Number of shares represented by one depositary shares" } } }, "localname": "NumberOfSharesRepresentedByOneDepositaryShares", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_NumberOfSharesSurrenderedAndCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares surrendered and cancelled.", "label": "Number Of Shares Surrendered And Cancelled", "negatedLabel": "Shares surrendered and cancelled", "terseLabel": "Number of shares surrendered and cancelled" } } }, "localname": "NumberOfSharesSurrenderedAndCancelled", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "cntb_NumberOfSharesSurrenderedRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares surrendered related party.", "label": "Number Of Shares Surrendered Related Party", "terseLabel": "Ordinary shares surrendered, related party" } } }, "localname": "NumberOfSharesSurrenderedRelatedParty", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_NumberOfTreasuryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares.", "label": "Number Of Treasury Shares", "terseLabel": "Number of treasury shares" } } }, "localname": "NumberOfTreasuryShares", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_OfficeEquipmentFurnitureAndOthersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office equipment, furniture and others.", "label": "Office Equipment Furniture And Others [Member]", "terseLabel": "Office Equipment, Furniture and Others" } } }, "localname": "OfficeEquipmentFurnitureAndOthersMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cntb_OfficeExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 6.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Office expenses.", "label": "Office Expenses", "terseLabel": "Office expenses" } } }, "localname": "OfficeExpenses", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "cntb_OfficeRentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office rent.", "label": "Office Rent [Member]", "terseLabel": "Office Rent" } } }, "localname": "OfficeRentMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "domainItemType" }, "cntb_OtherIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other income expense.", "label": "Other Income Expense [Abstract]" } } }, "localname": "OtherIncomeExpenseAbstract", "nsuri": "http://www.connectbiopharm.com/20220630", "xbrltype": "stringItemType" }, "cntb_OtherIncomeLossesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other income losses net.", "label": "Other Income (Losses) Net [Abstract]" } } }, "localname": "OtherIncomeLossesNetAbstract", "nsuri": "http://www.connectbiopharm.com/20220630", "xbrltype": "stringItemType" }, "cntb_OtherNonCurrentAssetsOther": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails": { "order": 0.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other non-current assets other.", "label": "Other Non-current Assets Other", "terseLabel": "Others" } } }, "localname": "OtherNonCurrentAssetsOther", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_OtherNonOperatingIncomesExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other non-operating incomes (expenses).", "label": "Other Non Operating Incomes Expenses", "negatedLabel": "Other loss", "terseLabel": "Other (loss)/gain" } } }, "localname": "OtherNonOperatingIncomesExpenses", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "cntb_OtherPayablesAndAccruals": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other payables and accruals.", "label": "Other Payables And Accruals", "terseLabel": "Other payables and accruals", "totalLabel": "Other payables and accruals" } } }, "localname": "OtherPayablesAndAccruals", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cntb_OtherPayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables and accruals.", "label": "Other Payables and Accruals [Abstract]" } } }, "localname": "OtherPayablesAndAccrualsAbstract", "nsuri": "http://www.connectbiopharm.com/20220630", "xbrltype": "stringItemType" }, "cntb_OtherPayablesAndAccrualsCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables and accruals current.", "label": "Other Payables and Accruals Current [Member]", "terseLabel": "Other Payables and Accruals" } } }, "localname": "OtherPayablesAndAccrualsCurrentMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_OtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables.", "label": "Other Payables [Member]", "terseLabel": "Other Payables" } } }, "localname": "OtherPayablesMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "cntb_OtherReceivablesAndPrepayments": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other receivables and prepayments.", "label": "Other Receivables And Prepayments", "terseLabel": "Other receivable and prepayments", "totalLabel": "Other receivables and prepayments" } } }, "localname": "OtherReceivablesAndPrepayments", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cntb_OtherReceivablesAndPrepaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other receivables and prepayments.", "label": "Other Receivables And Prepayments [Abstract]" } } }, "localname": "OtherReceivablesAndPrepaymentsAbstract", "nsuri": "http://www.connectbiopharm.com/20220630", "xbrltype": "stringItemType" }, "cntb_OtherReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other receivables.", "label": "Other Receivables [Member]", "terseLabel": "Other Receivables" } } }, "localname": "OtherReceivablesMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "cntb_PaymentForRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment for right of use assets.", "label": "Payment For Right Of Use Assets", "negatedLabel": "Payment in relation to right-of-use assets" } } }, "localname": "PaymentForRightOfUseAssets", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cntb_PaymentInRelationToListingExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment in relation to listing expenses.", "label": "Payment In Relation To Listing Expenses", "negatedLabel": "Payment in relation to listing expenses" } } }, "localname": "PaymentInRelationToListingExpenses", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cntb_PaymentMadeByHoldersOfPreferredSharesUponOrInConnectionWithConversionOfPreferredSharesIntoOrdinaryShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Made by Holders of Preferred Shares Upon or in Connection With Conversion of Preferred Shares into Ordinary Shares", "label": "Payment made by holders of preferred shares upon or in connection with conversion of preferred shares into ordinary shares" } } }, "localname": "PaymentMadeByHoldersOfPreferredSharesUponOrInConnectionWithConversionOfPreferredSharesIntoOrdinaryShares", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_PayrollWelfareAndBonusPayables": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails": { "order": 1.0, "parentTag": "cntb_OtherPayablesAndAccruals", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payroll, welfare and bonus payables.", "label": "Payroll Welfare And Bonus Payables", "terseLabel": "Payroll, welfare and bonus payables" } } }, "localname": "PayrollWelfareAndBonusPayables", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_PreferredSharesConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares conversion ratio.", "label": "Preferred Shares Conversion Ratio", "terseLabel": "Preferred shares conversion ratio" } } }, "localname": "PreferredSharesConversionRatio", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "cntb_PreferredSharesSubscriptionConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred shares, subscription consideration.", "label": "Preferred Shares Subscription Consideration", "terseLabel": "Subscription consideration" } } }, "localname": "PreferredSharesSubscriptionConsideration", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "monetaryItemType" }, "cntb_PreferredSharesSubscriptionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares, subscription date.", "label": "Preferred Shares Subscription Date", "terseLabel": "Date of subscription" } } }, "localname": "PreferredSharesSubscriptionDate", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "dateItemType" }, "cntb_PreferredSharesSubscriptionDateOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Shares Subscription Date One", "label": "Preferred Shares Subscription Date One", "terseLabel": "Date of subscription" } } }, "localname": "PreferredSharesSubscriptionDateOne", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "dateItemType" }, "cntb_PreferredSharesSubscriptionDateTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares subscription date two.", "label": "Preferred Shares Subscription Date Two", "terseLabel": "Date of subscription" } } }, "localname": "PreferredSharesSubscriptionDateTwo", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "dateItemType" }, "cntb_PrepaymentsForPurchaseOfNonCurrentAssets": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepayments for purchase of non-current assets.", "label": "Prepayments For Purchase Of Non Current Assets", "terseLabel": "Prepayments for purchase of non-current assets" } } }, "localname": "PrepaymentsForPurchaseOfNonCurrentAssets", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_PurchaseOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase of financial assets at fair value through other comprehensive income.", "label": "Purchase of Financial Assets at Fair Value Through Other Comprehensive Income", "negatedLabel": "Purchase of financial assets at fair value through other comprehensive income", "terseLabel": "Additions" } } }, "localname": "PurchaseOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInFinancialInstrumentsOfShorttermAndLongtermInvestmentsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cntb_PurchasePriceInterestOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase price interest of financial assets at fair value through other comprehensive income", "label": "Purchase price interest of financial assets at fair value through other comprehensive income", "terseLabel": "Interest in purchase price" } } }, "localname": "PurchasePriceInterestOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInFinancialInstrumentsOfShorttermAndLongtermInvestmentsParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "cntb_RedemptionPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption price percentage.", "label": "Redemption price percentage" } } }, "localname": "RedemptionPricePercentage", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cntb_RepurchaseOfOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repurchase of ordinary shares.", "label": "Repurchase of Ordinary Shares", "negatedLabel": "Repurchase of ordinary shares, shares", "terseLabel": "Repurchase of ordinary shares", "verboseLabel": "Repurchase of ordinary shares, shares" } } }, "localname": "RepurchaseOfOrdinaryShares", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "sharesItemType" }, "cntb_RepurchaseOfOrdinarySharesValue": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 4.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Repurchase of ordinary shares value.", "label": "Repurchase Of Ordinary Shares Value", "negatedLabel": "Repurchase of ordinary shares value", "terseLabel": "Repurchase of ordinary shares value" } } }, "localname": "RepurchaseOfOrdinarySharesValue", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_ResearchAndDevelopmentExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development expenses.", "label": "Research And Development Expenses [Member]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensesMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "cntb_RestrictedNetAssetsAndParentCompanyCondensedFinancialInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted net assets and parent company condensed financial information.", "label": "Restricted Net Assets And Parent Company Condensed Financial Information [Abstract]" } } }, "localname": "RestrictedNetAssetsAndParentCompanyCondensedFinancialInformationAbstract", "nsuri": "http://www.connectbiopharm.com/20220630", "xbrltype": "stringItemType" }, "cntb_RevenueFromGovernmentAsAnIncentiveForResearchAndDevelopment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from government as an incentive for research and development.", "label": "Revenue from government as an incentive for research and development" } } }, "localname": "RevenueFromGovernmentAsAnIncentiveForResearchAndDevelopment", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_RevenueFromGovernmentGrantsFromOtherSubsidies": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from government grants from other subsidies.", "label": "Grants received from other subsidies" } } }, "localname": "RevenueFromGovernmentGrantsFromOtherSubsidies", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_RightOfUseAssetsAccumulatedDepreciation": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails": { "order": 1.0, "parentTag": "ifrs-full_RightofuseAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Right of use assets accumulated depreciation.", "label": "Right of use Assets Accumulated Depreciation", "negatedTerseLabel": "Accumulated deprecation" } } }, "localname": "RightOfUseAssetsAccumulatedDepreciation", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_RiskFreeInterestRateMeasurementInputMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk-Free interest rate, measurement input.", "label": "Risk Free Interest Rate Measurement Input [Member]", "terseLabel": "Risk-Free Interest Rate" } } }, "localname": "RiskFreeInterestRateMeasurementInputMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "cntb_ScheduleOfDebtInvestmentsRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of debt investments recognized in profit or loss and other comprehensive income.", "label": "Schedule of Debt Investments Recognized in Profit or Loss and Other Comprehensive Income Explanatory", "terseLabel": "Schedule of Debt Investments Recognized in Profit or Loss and Other Comprehensive Income" } } }, "localname": "ScheduleOfDebtInvestmentsRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "cntb_ScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of financial assets at fair value through comprehensive income.", "label": "Schedule of Financial Assets at Fair Value Through Comprehensive Income Explanatory", "terseLabel": "Schedule of Financial Assets at Fair Value Through Comprehensive Income" } } }, "localname": "ScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeExplanatory", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "cntb_SeriesAPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A preferred shares.", "label": "Series A Preferred Shares [Member]", "terseLabel": "Series A Preferred Shares" } } }, "localname": "SeriesAPreferredSharesMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "cntb_SeriesBPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B preferred shares.", "label": "Series B Preferred Shares [Member]", "terseLabel": "Series B Preferred Shares" } } }, "localname": "SeriesBPreferredSharesMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "cntb_SeriesCPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series c preferred shares.", "label": "Series C Preferred Shares [Member]", "terseLabel": "Series C Preferred Shares", "verboseLabel": "Series C Preferred Shares" } } }, "localname": "SeriesCPreferredSharesMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "cntb_SeriesPreAPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series Pre-A preferred shares.", "label": "Series Pre A Preferred Shares [Member]", "terseLabel": "Series Pre-A Preferred Shares" } } }, "localname": "SeriesPreAPreferredSharesMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "domainItemType" }, "cntb_SettlmentOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Settlment of Financial Assets at Fair Value through Other Comprehensive Income", "label": "Settlment of Financial Assets at Fair Value through Other Comprehensive Income", "terseLabel": "Settlements" } } }, "localname": "SettlmentOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInFinancialInstrumentsOfShorttermAndLongtermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_ShareBasedCompensationReserve": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based compensation reserve.", "label": "Share-Based Compensation Reserve", "terseLabel": "Share-based compensation reserve" } } }, "localname": "ShareBasedCompensationReserve", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cntb_ShareBasedCompensationToAdditionalSeriesCPreferredShareholderFinancialInstrumentsWithPreferredRights": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation to additional series C preferred shareholder financial instruments with preferred rights.", "label": "Share Based Compensation To Additional Series C Preferred Shareholder Financial Instruments With Preferred Rights", "terseLabel": "Share-based compensation to additional Series C preferred shareholder", "verboseLabel": "Share-based compensation to additional Series C preferred shareholder" } } }, "localname": "ShareBasedCompensationToAdditionalSeriesCPreferredShareholderFinancialInstrumentsWithPreferredRights", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "monetaryItemType" }, "cntb_SharesReservedForFutureIssuanceUnderTwoThousandNineteenStockIncentivePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares reserved for future issuance under 2019 stock incentive plan.", "label": "Shares Reserved for Future Issuance under Two Thousand Nineteen Stock Incentive Plan", "terseLabel": "Shares reserved for future issuance under 2019 Stock Incentive plan" } } }, "localname": "SharesReservedForFutureIssuanceUnderTwoThousandNineteenStockIncentivePlan", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cntb_SharesSurrenderedAndCancelledConsiderationValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares surrendered and cancelled, consideration value.", "label": "Shares Surrendered And Cancelled Consideration Value", "terseLabel": "Shares surrendered and cancelled, consideration value" } } }, "localname": "SharesSurrenderedAndCancelledConsiderationValue", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Incentive Plan.", "label": "Stock Incentive Plan [Member]", "terseLabel": "Stock Incentive Plan" } } }, "localname": "StockIncentivePlanMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "domainItemType" }, "cntb_SummaryOfChangesInFinancialInstrumentsOfShortTermAndLongTermInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Changes in Financial Instruments of Short-term and Long-term Investments", "label": "Summary of Changes in Financial Instruments of Short-term and Long-term Investments" } } }, "localname": "SummaryOfChangesInFinancialInstrumentsOfShortTermAndLongTermInvestments", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationTables" ], "xbrltype": "textBlockItemType" }, "cntb_SuzhouMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suzhou.", "label": "Suzhou [Member]", "terseLabel": "Suzhou" } } }, "localname": "SuzhouMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails" ], "xbrltype": "domainItemType" }, "cntb_TradePayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade payables.", "label": "Trade Payables [Member]", "terseLabel": "Trade Payables" } } }, "localname": "TradePayablesMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "cntb_TransactionsWithOwnersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transactions with owners.", "label": "Transactions With Owners [Abstract]", "terseLabel": "Transactions with owners" } } }, "localname": "TransactionsWithOwnersAbstract", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "stringItemType" }, "cntb_TwentyTwentyOneEmployeeSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty twenty one employee share purchase plan.", "label": "Twenty Twenty One Employee Share Purchase Plan [Member]", "terseLabel": "2021 Employee Share Purchase Plan" } } }, "localname": "TwentyTwentyOneEmployeeSharePurchasePlanMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_TwentyTwentyOneStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty twenty one stock incentive plan.", "label": "2021 Stock Incentive Plan" } } }, "localname": "TwentyTwentyOneStockIncentivePlanMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_TwoThousandNineteenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Stock Incentive Plan.", "label": "Two Thousand Nineteen Stock Incentive Plan [Member]", "terseLabel": "2019 Stock Incentive Plan" } } }, "localname": "TwoThousandNineteenStockIncentivePlanMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_TwoThousandTwentyOneStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one stock incentive plan.", "label": "Two Thousand Twenty One Stock Incentive Plan [Member]", "terseLabel": "2021 Stock Incentive Plan" } } }, "localname": "TwoThousandTwentyOneStockIncentivePlanMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cntb_USTreasuryBillsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. treasury bills.", "label": "U.S. Treasury Bills Member", "terseLabel": "U.S. Treasury Bills" } } }, "localname": "USTreasuryBillsMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeOfDebtSecurit" ], "xbrltype": "domainItemType" }, "cntb_UnlistedDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unlisted Debt Securities", "label": "Unlisted Debt Securities Member", "terseLabel": "Unlisted Debt Securities" } } }, "localname": "UnlistedDebtSecuritiesMember", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeOfDebtSecurit" ], "xbrltype": "domainItemType" }, "cntb_UnrealizedGainLossesFromInvestments": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrealized gain (losses) from investments.", "label": "Unrealized gain (losses) from investments", "terseLabel": "Unrealized losses from investments" } } }, "localname": "UnrealizedGainLossesFromInvestments", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "cntb_UnrecognizedUncertainTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized uncertain tax positions.", "label": "Unrecognized uncertain tax positions" } } }, "localname": "UnrecognizedUncertainTaxPositions", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cntb_WeightedAverageSharePriceShareOptionsGrantedAtConsolidation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average share price share options granted at consolidation.", "label": "Weighted Average Share Price Share Options Granted At Consolidation", "terseLabel": "Fair value of share based payment on grant date at consolidation" } } }, "localname": "WeightedAverageSharePriceShareOptionsGrantedAtConsolidation", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "cntb_WelfareExpenses": { "auth_ref": [], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Welfare expenses.", "label": "Welfare Expenses", "terseLabel": "Welfare expenses" } } }, "localname": "WelfareExpenses", "nsuri": "http://www.connectbiopharm.com/20220630", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails" ], "xbrltype": "monetaryItemType" }, "country_AU": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AUSTRALIA", "terseLabel": "Australia", "verboseLabel": "Australian Dollar deposit" } } }, "localname": "AU", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "PRC", "verboseLabel": "RMB deposits" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "US Federal Corporate Income Tax", "verboseLabel": "USD deposits" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "verboseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation Date Of Incorporation", "terseLabel": "Date of incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "auth_ref": [ "r50", "r58", "r90", "r97", "r100" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated depreciation and amortisation [member]", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationAndAmortisationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated Other Comprehensive Income", "negatedLabel": "Accumulated losses", "terseLabel": "Accumulated losses", "totalLabel": "Total accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Losses" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions Other Than Through Business Combinations Property Plant And Equipment", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsToRightofuseAssets": { "auth_ref": [ "r159" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Additions to right-of-use assets", "terseLabel": "Additions" } } }, "localname": "AdditionsToRightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AddressOfRegisteredOfficeOfEntity": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The address at which the entity's office is registered." } }, "en-us": { "role": { "label": "Address Of Registered Office Of Entity", "terseLabel": "Address of registered office" } } }, "localname": "AddressOfRegisteredOfficeOfEntity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForAmortisationExpense": { "auth_ref": [ "r109" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Adjustments for amortisation expense", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AdjustmentsForAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": { "auth_ref": [ "r109" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 14.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other assets", "terseLabel": "Other non-current assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": { "auth_ref": [ "r107" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 13.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other operating receivables", "terseLabel": "Other receivables and prepayments" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "auth_ref": [ "r108" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Fair Value Gains Losses", "terseLabel": "Fair value changes of financial instruments with preferred rights" } } }, "localname": "AdjustmentsForFairValueGainsLosses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": { "auth_ref": [ "r107" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 15.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in other operating payables", "terseLabel": "Other payables and accruals" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "auth_ref": [ "r107" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 16.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Increase Decrease In Trade Account Payable", "terseLabel": "Trade payables" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments For Reconcile Profit Loss [Abstract]", "terseLabel": "Adjustments for:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r108" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Sharebased Payments", "terseLabel": "Share-based compensation expenses", "verboseLabel": "-Share-based compensation expenses" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "auth_ref": [ "r108", "r117" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Unrealised Foreign Exchange Losses Gains", "terseLabel": "Net foreign exchange differences" } } }, "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdministrativeExpense": { "auth_ref": [ "r2", "r39", "r79" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity classifies as being administrative." } }, "en-us": { "role": { "label": "Administrative Expense", "negatedLabel": "Administrative expenses" } } }, "localname": "AdministrativeExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised": { "auth_ref": [ "r186" ], "lang": { "en": { "role": { "documentation": "The aggregate difference between the fair value at initial recognition and the transaction price for financial instruments that is yet to be recognised in profit or loss. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Aggregate Difference Between Fair Value At Initial Recognition And Amount Determined Using Valuation Technique Yet To Be Recognised", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedMeasurementMember": { "auth_ref": [ "r95", "r99", "r137" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated Measurement [Member]", "terseLabel": "Aggregated measurement [member]" } } }, "localname": "AggregatedMeasurementMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "auth_ref": [ "r62", "r138" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } }, "en-us": { "role": { "label": "All Levels Of Fair Value Hierarchy [Member]", "terseLabel": "All levels of fair value hierarchy [member]" } } }, "localname": "AllLevelsOfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r16", "r137", "r138", "r143", "r205", "r207" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets2": { "order": 1.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets 1", "periodEndLabel": "Assets at end of period", "periodStartLabel": "Assets at beginning of period", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "auth_ref": [ "r3", "r10" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Attribution Of Expenses By Nature To Their Function [Axis]", "terseLabel": "Attribution of expenses by nature to their function [axis]" } } }, "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BalancesWithBanks": { "auth_ref": [ "r115" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": { "order": 1.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash balances held at banks." } }, "en-us": { "role": { "label": "Balances with banks", "terseLabel": "Cash at bank" } } }, "localname": "BalancesWithBanks", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r83", "r84" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic Earnings Loss Per Share", "terseLabel": "Basic loss per share (RMB)", "totalLabel": "Total basic earnings (loss) per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLossPerShareScheduleOfNetBasicLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r148", "r149", "r151", "r175", "r196", "r217" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom Of Range [Member]", "terseLabel": "Bottom of range" } } }, "localname": "BottomOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CapitalCommitmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Commitments [Abstract]" } } }, "localname": "CapitalCommitmentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r50", "r55", "r90", "r91", "r96", "r97", "r98", "r99", "r100", "r182", "r188", "r189", "r226", "r228" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount [Axis]", "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r55", "r91", "r96", "r98", "r99", "r182", "r188", "r189", "r226", "r227" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Carrying Amount [Member]", "terseLabel": "Carrying amount [member]" } } }, "localname": "CarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r115" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "terseLabel": "Cumulative cash contributions", "totalLabel": "Total cash" } } }, "localname": "Cash", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash [abstract]", "terseLabel": "Cash at bank" } } }, "localname": "CashAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r15", "r115", "r133" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash And Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of the six months ended", "periodStartLabel": "Cash and cash equivalents at the beginning of the six months ended", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CashEquivalents": { "auth_ref": [ "r115" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": { "order": 0.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value." } }, "en-us": { "role": { "label": "Cash equivalents", "terseLabel": "Cash equivalents", "totalLabel": "Total cash equivalents" } } }, "localname": "CashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r101", "r116" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash Flows From Used In Financing Activities", "netLabel": "Net cash flows from (used in) financing activities", "terseLabel": "Cash flows", "totalLabel": "Net cash generated from financing activities", "verboseLabel": "Net cash generated from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r101", "r116" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash Flows From Used In Investing Activities", "netLabel": "Net cash flows from (used in) investing activities", "terseLabel": "Net cash used in investing activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r101", "r116" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash Flows From Used In Operating Activities", "negatedLabel": "Net operating cash outflow", "netLabel": "Net cash flows from (used in) operating activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities", "verboseLabel": "Net cash from/(used in) operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperations": { "auth_ref": [ "r109", "r117" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } }, "en-us": { "role": { "label": "Cash Flows From Used In Operations", "negatedLabel": "Net operating cash outflow", "netLabel": "Net cash flows from (used in) operations", "terseLabel": "Cash used in operations", "totalLabel": "Net cash used in operations", "verboseLabel": "Net operating cash outflow" } } }, "localname": "CashFlowsFromUsedInOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashOutflowForLeases": { "auth_ref": [ "r158" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for leases." } }, "en-us": { "role": { "label": "Cash outflow for leases", "terseLabel": "Payment for land use rights", "totalLabel": "Total cash outflow for leases", "verboseLabel": "Total cash outflow for leases" } } }, "localname": "CashOutflowForLeases", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Categories of current financial assets [abstract]", "verboseLabel": "Investments:" } } }, "localname": "CategoriesOfCurrentFinancialAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories Of Financial Assets [Axis]", "terseLabel": "Categories of financial assets [axis]" } } }, "localname": "CategoriesOfFinancialAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories Of Financial Liabilities [Axis]", "terseLabel": "Categories of financial liabilities [axis]" } } }, "localname": "CategoriesOfFinancialLiabilitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Categories of non-current financial assets [abstract]", "terseLabel": "Investments:" } } }, "localname": "CategoriesOfNoncurrentFinancialAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r87", "r89", "r146", "r161" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r87", "r146", "r161" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Classes Of Employee Benefits Expense [Abstract]" } } }, "localname": "ClassesOfEmployeeBenefitsExpenseAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "auth_ref": [ "r194", "r195", "r214", "r219", "r220", "r221" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Financial Assets [Axis]", "terseLabel": "Classes of financial assets [axis]" } } }, "localname": "ClassesOfFinancialAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeOfDebtSecurit", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r188", "r190", "r191", "r193" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Financial Instruments [Axis]", "terseLabel": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r188", "r190", "r191", "r193" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Classes Of Financial Instruments [Member]", "terseLabel": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r194", "r195", "r214", "r220" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Financial Liabilities [Axis]", "terseLabel": "Financial Liabilities at Amortized Cost" } } }, "localname": "ClassesOfFinancialLiabilitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Intangible Assets Other Than Goodwill [Axis]", "terseLabel": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfLiabilitiesAxis": { "auth_ref": [ "r146" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Liabilities [Axis]", "terseLabel": "Classes of liabilities [axis]" } } }, "localname": "ClassesOfLiabilitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Property Plant And Equipment [Axis]", "terseLabel": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Share Capital [Axis]", "terseLabel": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "axisDefault": "Share capital", "label": "Classes Of Share Capital [Member]", "terseLabel": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClosingForeignExchangeRate": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } }, "en-us": { "role": { "label": "Closing foreign exchange rate" } } }, "localname": "ClosingForeignExchangeRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components Of Equity [Axis]", "terseLabel": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax [Abstract]", "terseLabel": "Items that may be reclassified to profit or loss" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax [Abstract]", "terseLabel": "Items that will not be reclassified to profit or loss" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r4", "r30", "r122", "r124", "r127", "r132" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive Income", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income Attributable To [Abstract]", "terseLabel": "Total comprehensive loss attributable to:" } } }, "localname": "ComprehensiveIncomeAttributableToAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "auth_ref": [ "r4", "r32" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } }, "en-us": { "role": { "label": "Comprehensive Income Attributable To Owners Of Parent", "terseLabel": "Owners of the Company", "totalLabel": "Owners of the Company" } } }, "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComputerSoftwareMember": { "auth_ref": [ "r93" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Computer Software [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ConstructionInProgressMember": { "auth_ref": [ "r48" ], "lang": { "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Construction in progress [member]", "terseLabel": "Assets Under Construction", "verboseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ContractualCapitalCommitments": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } }, "en-us": { "role": { "label": "Contractual capital commitments", "terseLabel": "Equipment and intangible assets - Contracted but not provided for", "verboseLabel": "Capital commitments" } } }, "localname": "ContractualCapitalCommitments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CountryOfIncorporation": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The country in which the entity is incorporated." } }, "en-us": { "role": { "label": "Country Of Incorporation", "terseLabel": "Country of incorporation", "verboseLabel": "Place of incorporation" } } }, "localname": "CountryOfIncorporation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r17", "r127", "r128" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current Assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets [Abstract]", "terseLabel": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [ "r198" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails2": { "order": 1.0, "parentTag": "ifrs-full_FinancialAssets", "weight": 1.0 }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]" } }, "en-us": { "role": { "label": "Current financial assets at fair value through other comprehensive income", "terseLabel": "Financial assets at fair value through other comprehensive income", "totalLabel": "Total current financial assets at fair value through other comprehensive income", "verboseLabel": "Financial assets at fair value through other comprehensive income (current)" } } }, "localname": "CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current financial assets measured at fair value through other comprehensive income. [Refer: Financial assets measured at fair value through other comprehensive income]" } }, "en-us": { "role": { "label": "Current financial assets measured at fair value through other comprehensive income", "terseLabel": "Current assets" } } }, "localname": "CurrentFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeOfDebtSecurit" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r153" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails": { "order": 1.0, "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current Lease Liabilities", "terseLabel": "Lease liabilities", "verboseLabel": "Current" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r18", "r127", "r130" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current Liabilities", "negatedLabel": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaidExpenses": { "auth_ref": [ "r10" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails": { "order": 2.0, "parentTag": "cntb_OtherReceivablesAndPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } }, "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid expenses" } } }, "localname": "CurrentPrepaidExpenses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentRetentionPayables": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current retention payables. [Refer: Retention payables]" } }, "en-us": { "role": { "label": "Current retention payables", "terseLabel": "Amounts withheld from employees paychecks" } } }, "localname": "CurrentRetentionPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredIncomeIncludingContractLiabilities": { "auth_ref": [ "r16", "r22" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Deferred income including contract liabilities", "terseLabel": "Total grants", "totalLabel": "Total grants" } } }, "localname": "DeferredIncomeIncludingContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncomeSummaryOfOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationAndAmortisationExpense": { "auth_ref": [ "r1", "r3", "r39", "r134", "r203", "r209" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 7.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation and amortisation expense", "negatedLabel": "Depreciation and amortisation expense", "terseLabel": "Depreciation and amortization", "totalLabel": "Total depreciation and amortisation expense" } } }, "localname": "DepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "auth_ref": [ "r53", "r57" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation Property Plant And Equipment", "negatedLabel": "Depreciation" } } }, "localname": "DepreciationPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationRightofuseAssets": { "auth_ref": [ "r154" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } }, "en-us": { "role": { "label": "Depreciation, right-of-use assets", "negatedLabel": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "DepreciationRightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForCashFlowsExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for cash flows.\nEffective 2023-01-01: The description of the entity's material accounting policy information for cash flows." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Cash Flows Explanatory", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DescriptionOfAccountingPolicyForCashFlowsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for earnings per share.\nEffective 2023-01-01: The description of the entity's material accounting policy information for earnings per share." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Earnings Per Share Explanatory", "terseLabel": "Loss per share" } } }, "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.\nEffective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Employee Benefits Explanatory", "terseLabel": "Employee Benefits" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for expenses.\nEffective 2023-01-01: The description of the entity's material accounting policy information for expenses." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Expenses Explanatory", "terseLabel": "Administrative expenses" } } }, "localname": "DescriptionOfAccountingPolicyForExpensesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Financial Instruments Explanatory", "terseLabel": "Financial instruments with preferred rights" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Foreign Currency Translation Explanatory", "terseLabel": "Foreign currency translation", "verboseLabel": "Convenience Translation" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Government Grants", "terseLabel": "Government grants" } } }, "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Impairment Of Nonfinancial Assets Explanatory", "terseLabel": "Impairment of non-financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income tax." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Income Tax Explanatory", "terseLabel": "Current and deferred income tax" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Intangible Assets Other Than Goodwill Explanatory", "terseLabel": "Intangible assets" } } }, "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income and expense arising from interest.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income and expense arising from interest." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Interest Income And Expense Explanatory", "terseLabel": "Interest Income" } } }, "localname": "DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for issued capital. [Refer: Issued capital]\nEffective 2023-01-01: The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Issued Capital Explanatory", "terseLabel": "Share capital" } } }, "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Leases Explanatory", "terseLabel": "Leases" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Property Plant And Equipment Explanatory", "terseLabel": "Property, plant and equipment" } } }, "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Research And Development Expense Explanatory", "terseLabel": "Research and development expenses" } } }, "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for segment reporting.\nEffective 2023-01-01: The description of the entity's material accounting policy information for segment reporting." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Segment Reporting Explanatory", "terseLabel": "Segment Information" } } }, "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Sharebased Payment Transactions Explanatory", "terseLabel": "Share-based compensation" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for subsidiaries. [Refer: Subsidiaries [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for subsidiaries. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Subsidiaries Explanatory", "terseLabel": "Separate financial statements" } } }, "localname": "DescriptionOfAccountingPolicyForSubsidiariesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r215", "r223" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]\nEffective 2023-01-01: The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Trade And Other Payables Explanatory", "terseLabel": "Trade and other payables" } } }, "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Description Of Expected Volatility Share Options Granted", "terseLabel": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The option life of share options granted." } }, "en-us": { "role": { "label": "Description Of Option Life Share Options Granted", "terseLabel": "Option life" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Description Of Risk Free Interest Rate Share Options Granted", "terseLabel": "Risk-free interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Accounting Judgements And Estimates Explanatory", "terseLabel": "Critical Accounting Estimates and Judgements" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCriticalAccountingEstimatesAndJudgements" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Attribution Of Expenses By Nature To Their Function [Abstract]" } } }, "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure Of Cash And Cash Equivalents Explanatory", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalents1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashFlowStatementExplanatory": { "auth_ref": [ "r119" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for a statement of cash flows." } }, "en-us": { "role": { "label": "Disclosure Of Cash Flow Statement Explanatory", "terseLabel": "Cash Flow Information" } } }, "localname": "DisclosureOfCashFlowStatementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital [Abstract]" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital Explanatory", "terseLabel": "Schedule of Share Capital and Share Premium" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital [Line Items]", "terseLabel": "Disclosure Of Classes Of Share Capital [Line Items]" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital [Table]", "terseLabel": "Disclosure Of Classes Of Share Capital [Table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments." } }, "en-us": { "role": { "label": "Disclosure Of Commitments Explanatory", "terseLabel": "Commitments" } } }, "localname": "DisclosureOfCommitmentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of credit risk exposure [line items]" } } }, "localname": "DisclosureOfCreditRiskExposureLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureTable": { "auth_ref": [ "r191" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the credit risk exposure." } }, "en-us": { "role": { "label": "Disclosure of credit risk exposure [table]" } } }, "localname": "DisclosureOfCreditRiskExposureTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Defined Benefit Plans [Line Items]", "terseLabel": "Disclosure Of Defined Benefit Plans [Line Items]" } } }, "localname": "DisclosureOfDefinedBenefitPlansLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } }, "en-us": { "role": { "label": "Disclosure Of Defined Benefit Plans [Table]", "terseLabel": "Disclosure Of Defined Benefit Plans [Table]" } } }, "localname": "DisclosureOfDefinedBenefitPlansTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disclosure Of Detailed Information About Property Plant And Equipment Explanatory", "terseLabel": "Summary of Property, Plant and Equipment" } } }, "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r86" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure Of Earnings Per Share Explanatory", "terseLabel": "Loss Per Share" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLossPerShare1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for employee benefits." } }, "en-us": { "role": { "label": "Disclosure Of Employee Benefits Explanatory", "terseLabel": "Employee Benefit Expenses" } } }, "localname": "DisclosureOfEmployeeBenefitsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureEmployeeBenefitExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r43" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure Of Events After Reporting Period Explanatory", "terseLabel": "Events After the Reporting Period" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureEventsAfterReportingPeriod" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Disclosure Of Expenses By Nature Explanatory", "terseLabel": "Expenses by Nature" } } }, "localname": "DisclosureOfExpensesByNatureExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNature" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfExpensesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of expenses." } }, "en-us": { "role": { "label": "Disclosure Of Expenses Explanatory", "terseLabel": "Summary of Expenses by Nature" } } }, "localname": "DisclosureOfExpensesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": { "auth_ref": [ "r150" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for fair value measurement." } }, "en-us": { "role": { "label": "Disclosure of fair value measurement [text block]", "terseLabel": "Fair Value Estimation" } } }, "localname": "DisclosureOfFairValueMeasurementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [abstract]" } } }, "localname": "DisclosureOfFairValueMeasurementOfAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } }, "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Summary of Financial Instruments Carried at Fair Value by Level of Inputs to Valuation Techniques" } } }, "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Financial Assets [Line Items]", "terseLabel": "Disclosure Of Financial Assets [Line Items]" } } }, "localname": "DisclosureOfFinancialAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "auth_ref": [ "r196" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } }, "en-us": { "role": { "label": "Disclosure Of Financial Assets [Table]", "terseLabel": "Disclosure Of Financial Assets [Table]" } } }, "localname": "DisclosureOfFinancialAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Financial Instruments [Abstract]" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Financial Instruments [Line Items]", "terseLabel": "Disclosure Of Financial Instruments [Line Items]" } } }, "localname": "DisclosureOfFinancialInstrumentsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeOfDebtSecurit", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "auth_ref": [ "r187", "r190", "r196" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } }, "en-us": { "role": { "label": "Disclosure Of Financial Instruments [Table]", "terseLabel": "Disclosure Of Financial Instruments [Table]" } } }, "localname": "DisclosureOfFinancialInstrumentsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeOfDebtSecurit", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "auth_ref": [ "r196" ], "lang": { "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Disclosure Of Financial Liabilities Explanatory", "terseLabel": "Movements of Financial Instruments with Preferred Rights" } } }, "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } }, "en-us": { "role": { "label": "Disclosure Of General Information About Financial Statements Explanatory", "terseLabel": "General Information and Basis of Presentation" } } }, "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGovernmentGrantsExplanatory": { "auth_ref": [ "r67" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for government grants." } }, "en-us": { "role": { "label": "Disclosure Of Government Grants Explanatory", "terseLabel": "Other Income" } } }, "localname": "DisclosureOfGovernmentGrantsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncome1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r47" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure Of Income Tax Explanatory", "terseLabel": "Income Taxes" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r178" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } }, "en-us": { "role": { "label": "Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period Explanatory", "terseLabel": "Summary of Key Assumptions for Options Granted" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Information About Key Management Personnel Explanatory", "terseLabel": "Summary of Key Management Personnel Compensation" } } }, "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Initial Application Of Standards Or Interpretations [Abstract]" } } }, "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]", "terseLabel": "Disclosure Of Initial Application Of Standards Or Interpretations [Line Items]" } } }, "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the initial application of standards or interpretations." } }, "en-us": { "role": { "label": "Disclosure Of Initial Application Of Standards Or Interpretations [Table]", "terseLabel": "Disclosure Of Initial Application Of Standards Or Interpretations [Table]" } } }, "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Disclosure of interests in subsidiaries [text block]", "terseLabel": "Summary of Direct or Indirect Interests in Principal Subsidiaries" } } }, "localname": "DisclosureOfInterestsInSubsidiariesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureGeneralInformationReorganizationAndBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r163", "r164" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "Disclosure of leases [text block]", "terseLabel": "Leases" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeases1" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Nonadjusting Events After Reporting Period [Abstract]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "auth_ref": [ "r41" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Share Options Explanatory", "terseLabel": "Summary of Options Outstanding" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]" } }, "en-us": { "role": { "label": "Disclosure Of Other Noncurrent Assets Explanatory", "terseLabel": "Schedule of Other non-current Assets" } } }, "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]" } }, "en-us": { "role": { "label": "Disclosure Of Prepayments And Other Assets Explanatory", "terseLabel": "Other Receivables and Prepayments" } } }, "localname": "DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepayments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment [Abstract]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment Explanatory", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment [Line Items]", "terseLabel": "Disclosure Of Property Plant And Equipment [Line Items]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment [Table]", "terseLabel": "Disclosure Of Property Plant And Equipment [Table]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [text block]", "terseLabel": "Schedule of Amounts Recognized in Consolidated Balance Sheets as Right-of-use Assets" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]", "terseLabel": "Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } }, "en-us": { "role": { "label": "Disclosure Of Quantitative Information About Rightofuse Assets [Table]", "terseLabel": "Disclosure Of Quantitative Information About Rightofuse Assets [Table]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } }, "en-us": { "role": { "label": "Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill Explanatory", "terseLabel": "Key Valuation Assumptions Used to Determine Fair Value of Financial Instruments with Preferred Rights" } } }, "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "auth_ref": [ "r114" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities Explanatory", "terseLabel": "Summary of Reconciliation of Liabilities Arising from Financing Activities" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r76" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure Of Related Party Explanatory", "terseLabel": "Related Party Transactions" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r28" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure Of Share Capital Reserves And Other Equity Interest Explanatory", "terseLabel": "Share Capital" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapital" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r165" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure Of Sharebased Payment Arrangements Explanatory", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsTable": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to significant unobservable inputs used in the fair value measurement of assets." } }, "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of assets [table]" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items]", "terseLabel": "Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Line Items]" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to significant unobservable inputs used in the fair value measurement of liabilities." } }, "en-us": { "role": { "label": "Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Table]", "terseLabel": "Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Liabilities [Table]" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r224" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure Of Summary Of Significant Accounting Policies Explanatory", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]", "terseLabel": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r176" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]", "terseLabel": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r74" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Transactions Between Related Parties Explanatory", "terseLabel": "Schedule of Significant Transactions and Balances with Related Parties" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Transactions Between Related Parties [Line Items]", "terseLabel": "Disclosure Of Transactions Between Related Parties [Line Items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r75" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure Of Transactions Between Related Parties [Table]", "terseLabel": "Disclosure Of Transactions Between Related Parties [Table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disposals, property, plant and equipment", "negatedLabel": "Disposal" } } }, "localname": "DisposalsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Loss per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r83" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Earnings Per Share Explanatory", "terseLabel": "Schedule of Basic Loss Per Share" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r110", "r111" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect Of Exchange Rate Changes On Cash And Cash Equivalents", "terseLabel": "Effects of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r1", "r3", "r39" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 5.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee Benefits Expense", "negatedLabel": "Employee benefits expense", "terseLabel": "Employee benefit expenses (Note 6)", "totalLabel": "Employee benefit expenses", "verboseLabel": "Employee benefit expenses" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r16", "r21", "r121", "r123", "r137", "r138", "r143" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders' equity" } } }, "localname": "Equity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract] 1", "terseLabel": "SHAREHOLDERS\u2019 DEFICIT", "verboseLabel": "SHAREHOLDERS' EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r16" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity And Liabilities", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } }, "en-us": { "role": { "label": "Equity Attributable To Owners Of Parent [Member]", "terseLabel": "Total" } } }, "localname": "EquityAttributableToOwnersOfParentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [Member]", "terseLabel": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } }, "en-us": { "role": { "label": "Expected Dividend As Percentage Share Options Granted", "terseLabel": "Dividend yield" } } }, "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ExpenseByNature": { "auth_ref": [ "r39" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity." } }, "en-us": { "role": { "label": "Expense By Nature", "terseLabel": "Total expenses by nature", "totalLabel": "Total expenses, by nature" } } }, "localname": "ExpenseByNature", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseByNatureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense By Nature [Abstract]" } } }, "localname": "ExpenseByNatureAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r180" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } }, "en-us": { "role": { "label": "Expense From Sharebased Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets", "terseLabel": "Share-based compensation expenses", "totalLabel": "Total expense from share-based payment transactions" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "auth_ref": [ "r10" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense From Sharebased Payment Transactions With Employees", "terseLabel": "Share-based compensation expenses (Note 22)", "verboseLabel": "Share-based compensation expenses" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": { "auth_ref": [ "r157" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails": { "order": 2.0, "parentTag": "ifrs-full_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets." } }, "en-us": { "role": { "label": "Expense relating to leases of low-value assets for which recognition exemption has been used", "terseLabel": "Expense relating to leases of low-value assets that are not shown above as short-term leases" } } }, "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": { "auth_ref": [ "r156" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails": { "order": 1.0, "parentTag": "ifrs-full_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease." } }, "en-us": { "role": { "label": "Expense relating to short-term leases for which recognition exemption has been used", "terseLabel": "Expense relating to short-term leases" } } }, "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)." } }, "en-us": { "role": { "label": "Explanation Of Effect Of Sharebased Payments On Profit Or Loss", "terseLabel": "Summary of Share-Based Compensation Expenses" } } }, "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement": { "auth_ref": [ "r166" ], "lang": { "en": { "role": { "documentation": "The description of a share-based payment arrangement that existed at any time during the reporting period. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description of share-based payment arrangement", "terseLabel": "Description of share-based payment arrangement" } } }, "localname": "ExplanationOfShareOptionsInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r33" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 0.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance Costs", "negatedLabel": "Finance cost", "negatedTotalLabel": "Finance costs" } } }, "localname": "FinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r36" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance Income", "terseLabel": "Finance income" } } }, "localname": "FinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncomeCost": { "auth_ref": [ "r36" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0 }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance (loss) / income - net", "negatedLabel": "Finance income - net", "terseLabel": "Finance costs - net", "totalLabel": "Finance income - net", "verboseLabel": "Finance (loss) / income - net" } } }, "localname": "FinanceIncomeCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssets": { "auth_ref": [ "r185", "r188", "r189", "r191", "r192" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial Assets", "periodEndLabel": "Financial assets at end of period", "periodStartLabel": "Financial assets at beginning of period", "terseLabel": "Financial Assets", "totalLabel": "Total assets", "verboseLabel": "FINANCIAL ASSETS" } } }, "localname": "FinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtAmortisedCostMember": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]" } }, "en-us": { "role": { "label": "Financial Assets At Amortised Cost [Member]", "terseLabel": "Financial Assets at Amortized Cost" } } }, "localname": "FinancialAssetsAtAmortisedCostMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsAtFairValue": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Financial assets measured at fair value" } } }, "localname": "FinancialAssetsAtFairValue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValueMember": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets measured at fair value class. [Refer: Financial assets; At fair value [member]]" } }, "en-us": { "role": { "label": "Financial Assets At Fair Value [Member]", "terseLabel": "Financial Assets at FVPL" } } }, "localname": "FinancialAssetsAtFairValueMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial assets at fair value through other comprehensive income [abstract]" } } }, "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Assets At Fair Value Through Profit Or Loss [Abstract]", "terseLabel": "Assets" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLossAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "auth_ref": [ "r197" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Financial Assets At Fair Value Through Profit Or Loss Category [Member]", "terseLabel": "Financial Assets at Fair Value through Profit or Loss" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsCategoryMember": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial Assets Category [Member]", "terseLabel": "Financial assets, category [member]" } } }, "localname": "FinancialAssetsCategoryMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets measured at fair value through other comprehensive income", "periodEndLabel": "Closing Balance" } } }, "localname": "FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInFinancialInstrumentsOfShorttermAndLongtermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsMember": { "auth_ref": [ "r194", "r195", "r214", "r219", "r220", "r221" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial Assets [Member]", "terseLabel": "Financial assets, class [member]" } } }, "localname": "FinancialAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeOfDebtSecurit", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]" } }, "en-us": { "role": { "label": "Financial Liabilities At Amortised Cost [Member]", "terseLabel": "Financial Liabilities at Amortized Cost" } } }, "localname": "FinancialLiabilitiesAtAmortisedCostMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "auth_ref": [ "r185" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities, at fair value", "terseLabel": "Financial liabilities measured at fair value" } } }, "localname": "FinancialLiabilitiesAtFairValue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValueMember": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]" } }, "en-us": { "role": { "label": "Financial Liabilities At Fair Value [Member]", "terseLabel": "Financial Liabilities at Amortized Cost", "verboseLabel": "Financial Liabilities at FVPL" } } }, "localname": "FinancialLiabilitiesAtFairValueMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial Liabilities Category [Member]", "terseLabel": "Financial liabilities, category [member]" } } }, "localname": "FinancialLiabilitiesCategoryMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesMember": { "auth_ref": [ "r194", "r195", "r214", "r220" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Financial Liabilities [Member]", "terseLabel": "Financial liabilities, class [member]" } } }, "localname": "FinancialLiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ForeignCountriesMember": { "auth_ref": [ "r210", "r211" ], "lang": { "en": { "role": { "documentation": "This member stands for countries outside the entity's country of domicile. [Refer: Country of domicile [member]]" } }, "en-us": { "role": { "label": "Foreign countries [member]", "terseLabel": "Outside of PRC" } } }, "localname": "ForeignCountriesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment": { "auth_ref": [ "r38" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Gains (losses) on disposals of property, plant and equipment", "negatedLabel": "Loss on disposal of property, plant and equipment", "netLabel": "Net gains (losses) on disposals of property, plant and equipment", "terseLabel": "(Gain)/Loss on disposal of PPE", "verboseLabel": "-(Gain)/Loss on disposal of PPE" } } }, "localname": "GainsLossesOnDisposalsOfPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax": { "auth_ref": [ "r37" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Gains Losses On Exchange Differences On Translation Net Of Tax", "terseLabel": "Exchange differences", "verboseLabel": "Change in fair value due to foreign currency translation recognized in OCI" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationNetOfTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "auth_ref": [ "r12", "r68" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetDetails": { "order": 0.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss", "netLabel": "Net foreign exchange gain (loss)", "terseLabel": "Net foreign exchange gains/(losses) included in other gains/(losses)-net", "verboseLabel": "Net foreign exchange (losses)/gains" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r184" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Gains Losses On Financial Liabilities At Fair Value Through Profit Or Loss", "terseLabel": "Fair value loss of financial instruments with preferred rights", "totalLabel": "Total gains (losses) on financial liabilities at fair value through profit or loss" } } }, "localname": "GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementAssets": { "auth_ref": [ "r141" ], "lang": { "en": { "role": { "documentation": "The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of assets. [Refer: At fair value [member]; Other comprehensive income]" } }, "en-us": { "role": { "label": "Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, assets", "terseLabel": "Change in fair value debited to other comprehensive income / (loss)", "totalLabel": "Total gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, assets", "verboseLabel": "Losses recognized in other comprehensive income related to debt investments" } } }, "localname": "GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInFinancialInstrumentsOfShorttermAndLongtermInvestmentsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfDebtInvestmentsRecognizedInProfitOrLossAndOtherComprehensiveIncom" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets": { "auth_ref": [ "r140" ], "lang": { "en": { "role": { "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of assets. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets", "terseLabel": "Investment income credited to profit or loss (Note 8)", "totalLabel": "Total gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets" } } }, "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r60", "r152", "r212", "r218" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical Areas [Axis]", "terseLabel": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r60", "r152", "r212", "r218" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical Areas [Member]", "terseLabel": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GovernmentGrants": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]" } }, "en-us": { "role": { "label": "Government Grants", "terseLabel": "Government grants" } } }, "localname": "GovernmentGrants", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncomeSummaryOfOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GovernmentMember": { "auth_ref": [ "r213" ], "lang": { "en": { "role": { "documentation": "This member stands for a government, government agencies and similar bodies whether local, national or international." } }, "en-us": { "role": { "label": "Government [member]", "terseLabel": "China Government" } } }, "localname": "GovernmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r50", "r90", "r97", "r100", "r182", "r189", "r191", "r192", "r226", "r228" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Gross Carrying Amount [Member]", "terseLabel": "Cost" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": { "auth_ref": [ "r147" ], "lang": { "en": { "role": { "documentation": "This member stands for the historical volatility for shares used as a measurement input." } }, "en-us": { "role": { "label": "Historical Volatility For Shares Measurement Input [Member]", "terseLabel": "Expected Volatility", "verboseLabel": "Volatility" } } }, "localname": "HistoricalVolatilityForSharesMeasurementInputMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r34", "r44", "r45", "r46", "r80", "r136", "r204" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 0.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Income Tax Expense Continuing Operations", "negatedLabel": "Income tax expense", "negatedTerseLabel": "Tax income (expense)", "terseLabel": "Income tax expense", "totalLabel": "Income tax expense", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r115" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes", "netLabel": "Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net increase / (decrease) in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxEntitysOwnEquityInstruments": { "auth_ref": [ "r144" ], "lang": { "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of the entity's own equity instruments, recognised in profit or loss before tax, due to a reasonably possible decrease in an unobservable input. [Refer: Tax income (expense)]" } }, "en-us": { "role": { "label": "Loss before income tax lower due to change in unobservable input" } } }, "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxEntitysOwnEquityInstruments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxEntitysOwnEquityInstruments": { "auth_ref": [ "r144" ], "lang": { "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of the entity's own equity instruments, recognised in profit or loss before tax, due to a reasonably possible increase in an unobservable input. [Refer: Tax income (expense)]" } }, "en-us": { "role": { "label": "Loss before income tax higher due to change in unobservable input" } } }, "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxEntitysOwnEquityInstruments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Increase Decrease In Number Of Ordinary Shares Issued", "terseLabel": "Issuance of shares to Co-founders, shares", "verboseLabel": "Issuance of Ordinary Shares, shares" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_IncreaseDecreaseThroughAmountsRecognisedInProfitOrLossAggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised": { "auth_ref": [ "r186", "r201" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the aggregate difference between the fair value at initial recognition and the transaction price of financial instruments yet to be recognised in profit or loss resulting from amounts recognised in profit or loss. [Refer: Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Increase Decrease Through Amounts Recognised In Profit Or Loss Aggregate Difference Between Fair Value At Initial Recognition And Amount Determined Using Valuation Technique Yet To Be Recognised", "terseLabel": "Change in fair value recognized in profit or loss" } } }, "localname": "IncreaseDecreaseThroughAmountsRecognisedInProfitOrLossAggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "auth_ref": [ "r7" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 2.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } }, "en-us": { "role": { "label": "Increase (decrease) through conversion of convertible instruments, equity", "terseLabel": "Conversion from preferred shares", "verboseLabel": "Conversion from preferred shares to ordinary shares" } } }, "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "auth_ref": [ "r7" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 3.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } }, "en-us": { "role": { "label": "Increase Decrease Through Exercise Of Options", "terseLabel": "Exercise of stock options" } } }, "localname": "IncreaseDecreaseThroughExerciseOfOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, property, plant and equipment", "terseLabel": "Exchange difference" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNewTransactionsAggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised": { "auth_ref": [ "r186", "r201" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the aggregate difference between the fair value at initial recognition and the transaction price of financial instruments yet to be recognised in profit or loss resulting from new transactions. [Refer: Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Increase Decrease Through New Transactions Aggregate Difference Between Fair Value At Initial Recognition And Amount Determined Using Valuation Technique Yet To Be Recognised", "terseLabel": "Issuance of Series C Preferred Shares" } } }, "localname": "IncreaseDecreaseThroughNewTransactionsAggregateDifferenceBetweenFairValueAtInitialRecognitionAndAmountDeterminedUsingValuationTechniqueYetToBeRecognised", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsMovementsOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r6" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 1.0, "parentTag": "cntb_ContributionsByAndDistributionsToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase Decrease Through Sharebased Payment Transactions", "terseLabel": "Share-based compensation", "verboseLabel": "Share based compensation" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]" } }, "en-us": { "role": { "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment", "terseLabel": "Transfers" } } }, "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InsuranceExpense": { "auth_ref": [ "r10" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 2.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from purchased insurance." } }, "en-us": { "role": { "label": "Insurance expense", "terseLabel": "Insurance" } } }, "localname": "InsuranceExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwill": { "auth_ref": [ "r16" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets and goodwill", "periodEndLabel": "Intangible assets and goodwill at end of period", "periodStartLabel": "Intangible assets and goodwill at beginning of period", "terseLabel": "Intangible assets", "totalLabel": "Total intangible assets and goodwill" } } }, "localname": "IntangibleAssetsAndGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r88", "r92", "r161" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible Assets Other Than Goodwill [Member]", "terseLabel": "Intangible assets other than goodwill [member]" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestExpense": { "auth_ref": [ "r135", "r202", "r209" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from interest." } }, "en-us": { "role": { "label": "Interest expense", "totalLabel": "Total interest expense amount recognized" } } }, "localname": "InterestExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "auth_ref": [ "r155" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails": { "order": 0.0, "parentTag": "ifrs-full_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Interest expense on lease liabilities", "negatedLabel": "Interest for lease liabilities", "terseLabel": "Interest expense", "verboseLabel": "Interest for lease liabilities" } } }, "localname": "InterestExpenseOnLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedStatementsOfLossInAdditionToDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of interest income on financial assets designated at fair value through profit or loss. [Refer: Interest income; Financial assets at fair value through profit or loss, designated upon initial recognition or subsequently]" } }, "en-us": { "role": { "label": "Interest income on financial assets designated at fair value through profit or loss" } } }, "localname": "InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfDebtInvestmentsRecognizedInProfitOrLossAndOtherComprehensiveIncom" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "auth_ref": [ "r112" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } }, "en-us": { "role": { "label": "Interest received, classified as operating activities", "terseLabel": "Interest received" } } }, "localname": "InterestReceivedClassifiedAsOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentIncome": { "auth_ref": [ "r36", "r77" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of investment income, such as interest and dividends." } }, "en-us": { "role": { "label": "Investment income", "terseLabel": "Investment income from investments at fair value through profit and loss and wealth management products" } } }, "localname": "InvestmentIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r21" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued Capital", "terseLabel": "Share capital", "totalLabel": "Total issued capital" } } }, "localname": "IssuedCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued Capital [Member]", "terseLabel": "Share Capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_IssuedCapitalOrdinaryShares": { "auth_ref": [ "r21" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Issued Capital Ordinary Shares", "terseLabel": "Value of share capital" } } }, "localname": "IssuedCapitalOrdinaryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r73" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation", "totalLabel": "Key management personnel compensation" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": { "auth_ref": [ "r71" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails": { "order": 3.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, other long-term employee benefits", "terseLabel": "Welfare, housing funds and other" } } }, "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r70" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails": { "order": 2.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation Postemployment Benefits", "terseLabel": "Contributions to defined benefit plan" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r72" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails": { "order": 1.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation Sharebased Payment", "terseLabel": "Share-based compensation expenses" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r69" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails": { "order": 0.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation Shortterm Employee Benefits", "terseLabel": "Wages, salaries and bonuses" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfKeyManagementPersonnelCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r153" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease Liabilities", "terseLabel": "Lease liabilities", "totalLabel": "Total lease liabilities", "verboseLabel": "Aggregate lease obligation over lease term" } } }, "localname": "LeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease liabilities [abstract]" } } }, "localname": "LeaseLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_LeaseLiabilitiesMember": { "auth_ref": [ "r113", "r118" ], "lang": { "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease Liabilities [Member]", "terseLabel": "Lease Liabilities" } } }, "localname": "LeaseLiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseholdImprovementsMember": { "auth_ref": [ "r48" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } }, "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level1OfFairValueHierarchyMember": { "auth_ref": [ "r62", "r138" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } }, "en-us": { "role": { "label": "Level1 Of Fair Value Hierarchy [Member]", "terseLabel": "Level 1" } } }, "localname": "Level1OfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level2OfFairValueHierarchyMember": { "auth_ref": [ "r138" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } }, "en-us": { "role": { "label": "Level2 Of Fair Value Hierarchy [Member]", "terseLabel": "Level 2" } } }, "localname": "Level2OfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level3OfFairValueHierarchyMember": { "auth_ref": [ "r138" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } }, "en-us": { "role": { "label": "Level3 Of Fair Value Hierarchy [Member]", "terseLabel": "Level 3" } } }, "localname": "Level3OfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r62", "r138" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels Of Fair Value Hierarchy [Axis]", "terseLabel": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r16", "r137", "r138", "r143", "r205", "r208" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets2": { "order": 0.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities 1", "negatedLabel": "Liabilities", "periodEndLabel": "At December 31, 2021", "periodStartLabel": "At January 1, 2021", "terseLabel": "Net liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "auth_ref": [ "r114" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Liabilities Arising From Financing Activities [Axis]", "terseLabel": "Liabilities arising from financing activities [axis]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": { "auth_ref": [ "r114" ], "lang": { "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Liabilities Arising From Financing Activities [Member]", "terseLabel": "Liabilities arising from financing activities [member]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialInstrumentsByCategoryScheduleOfFinancialInstrumentsByCategoryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LiabilitiesMember": { "auth_ref": [ "r146" ], "lang": { "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } }, "en-us": { "role": { "label": "Liabilities [Member]", "terseLabel": "Liabilities [member]" } } }, "localname": "LiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LineItemsByFunctionMember": { "auth_ref": [ "r3", "r10" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } }, "en-us": { "role": { "label": "Line Items By Function [Member]", "terseLabel": "Line items by function [member]" } } }, "localname": "LineItemsByFunctionMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesIncludedInConsolidatedStatementsOfLossDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major Components Of Tax Expense Income [Abstract]" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_MajorCustomersAxis": { "auth_ref": [ "r213" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Major customers [axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MajorCustomersMember": { "auth_ref": [ "r213" ], "lang": { "en": { "role": { "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used." } }, "en-us": { "role": { "label": "Customers [member]" } } }, "localname": "MajorCustomersMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "auth_ref": [ "r42" ], "lang": { "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Major ordinary share transactions [member]", "terseLabel": "Ordinary Share Options" } } }, "localname": "MajorOrdinaryShareTransactionsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MeasurementAxis": { "auth_ref": [ "r95", "r99", "r137" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Measurement [Axis]", "terseLabel": "Measurement [axis]" } } }, "localname": "MeasurementAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MiscellaneousNoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Miscellaneous Noncurrent Assets [Abstract]" } } }, "localname": "MiscellaneousNoncurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_NetAssetsLiabilities": { "auth_ref": [ "r10", "r125" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } }, "en-us": { "role": { "label": "Net Assets Liabilities", "netLabel": "Net assets (liabilities)", "totalLabel": "Net assets", "verboseLabel": "Net assets" } } }, "localname": "NetAssetsLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r41" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r41" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r17", "r127", "r129" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Noncurrent Assets 1", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent Assets [Abstract]", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [ "r198" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails2": { "order": 0.0, "parentTag": "ifrs-full_FinancialAssets", "weight": 1.0 }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]" } }, "en-us": { "role": { "label": "Non-current financial assets at fair value through other comprehensive income", "terseLabel": "Financial assets at fair value through other comprehensive income", "totalLabel": "Total non-current financial assets at fair value through other comprehensive income", "verboseLabel": "Financial assets at fair value through other comprehensive income (non-current)" } } }, "localname": "NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current financial assets measured at fair value through other comprehensive income. [Refer: Financial assets measured at fair value through other comprehensive income]" } }, "en-us": { "role": { "label": "Non-current financial assets measured at fair value through other comprehensive income", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughComprehensiveIncomeScheduleOfFinancialAssetsAtFairValueThroughComprehensiveIncomeOfDebtSecurit" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Non-current assets; Investments other than investments accounted for using equity method]" } }, "en-us": { "role": { "label": "Non-current investments other than investments accounted for using equity method", "terseLabel": "Long-term investments" } } }, "localname": "NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r153" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails": { "order": 0.0, "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0 }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Noncurrent Lease Liabilities", "terseLabel": "Lease liabilities", "verboseLabel": "Non-current" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsLeaseLiabilityDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r18", "r127", "r131" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Noncurrent Liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent Liabilities [Abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentPrepayments": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current prepayments. [Refer: Prepayments]" } }, "en-us": { "role": { "label": "Noncurrent Prepayments", "terseLabel": "Prepayments" } } }, "localname": "NoncurrentPrepayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentValueAddedTaxReceivables": { "auth_ref": [ "r20" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current value added tax receivables. [Refer: Value added tax receivables]" } }, "en-us": { "role": { "label": "Noncurrent Value Added Tax Receivables", "terseLabel": "Deductible value-added tax" } } }, "localname": "NoncurrentValueAddedTaxReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r167", "r171", "r175" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Outstanding Share Options", "periodEndLabel": "Number of Options, Options outstanding, Ending Balance", "periodStartLabel": "Number of Options, Options outstanding, Beginning Balance" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Exercisable In Sharebased Payment Arrangement", "terseLabel": "Number of Options, Options exercisable as of June 30, 2022" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r169" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Forfeited In Sharebased Payment Arrangement", "negatedLabel": "Number of Options, Forfeited during the six months ended June 30, 2022", "terseLabel": "Forfeited during the year" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r168" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Granted In Sharebased Payment Arrangement", "terseLabel": "Number of Options, Granted during the six months ended June 30, 2022", "verboseLabel": "Share options granted" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of preferred shares", "terseLabel": "Number of shares issued", "totalLabel": "Total number of shares issued", "verboseLabel": "NUMBER OF PREFERRED SHARES" } } }, "localname": "NumberOfSharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsSummaryOfSeriesOfFinancingsByIssuingPreferredSharesDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r24" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number Of Shares Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "terseLabel": "Ordinary shares", "verboseLabel": "Number of shares outstanding" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r26", "r83" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary Shares [Member]", "terseLabel": "Ordinary Shares" } } }, "localname": "OrdinarySharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income [Abstract]", "terseLabel": "Other comprehensive (loss)/income", "verboseLabel": "Comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r19", "r37" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other Comprehensive Income Net Of Tax Exchange Differences On Translation", "terseLabel": "Exchange differences on translation of foreign operations", "totalLabel": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations": { "auth_ref": [ "r37" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to exchange differences on translation of the financial statements of a parent company or a stand-alone entity to a different presentation currency. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other Comprehensive Income Net Of Tax Exchange Differences On Translation Other Than Translation Of Foreign Operations", "terseLabel": "Exchange differences on translation of foreign operations" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [ "r19", "r37" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to financial assets measured at fair value through other comprehensive income applying paragraph 4.1.2A of IFRS 9. [Refer: Financial assets measured at fair value through other comprehensive income; Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, financial assets measured at fair value through other comprehensive income", "terseLabel": "Changes in the fair value of debt instruments at fair value through other comprehensive income", "totalLabel": "Other comprehensive income, net of tax, financial assets measured at fair value through other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "auth_ref": [ "r35", "r40" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax", "totalLabel": "Other comprehensive (loss)/income, net of tax" } } }, "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherExpenseByNature": { "auth_ref": [ "r1", "r39" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 9.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Other Expense By Nature", "negatedTerseLabel": "Other expenses", "terseLabel": "Others" } } }, "localname": "OtherExpenseByNature", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherGainsLosses": { "auth_ref": [ "r1", "r2" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Gains Losses", "terseLabel": "Other (losses)/gains - net", "totalLabel": "Other (losses)/gains - net" } } }, "localname": "OtherGainsLosses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherLossesgainsNetScheduleOfOtherLossesgainsNetDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherIncome": { "auth_ref": [ "r1", "r2", "r78" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Income", "terseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentAssets": { "auth_ref": [ "r16" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } }, "en-us": { "role": { "label": "Other Noncurrent Assets", "terseLabel": "Other non-current assets", "totalLabel": "Other non-current assets" } } }, "localname": "OtherNoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherPayables": { "auth_ref": [ "r16" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails": { "order": 3.0, "parentTag": "cntb_OtherPayablesAndAccruals", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Payables", "terseLabel": "Other payables" } } }, "localname": "OtherPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherPayablesAndAccrualsScheduleOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReceivables": { "auth_ref": [ "r20" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails": { "order": 3.0, "parentTag": "cntb_OtherReceivablesAndPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Receivables", "terseLabel": "Others" } } }, "localname": "OtherReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReserves": { "auth_ref": [ "r21" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other Reserves", "terseLabel": "Other reserves" } } }, "localname": "OtherReserves", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReservesMember": { "auth_ref": [ "r8", "r27" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other Reserves [Member]", "terseLabel": "Other Reserves" } } }, "localname": "OtherReservesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par Value Per Share", "terseLabel": "Par value per share", "verboseLabel": "Par value" } } }, "localname": "ParValuePerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments Of Lease Liabilities Classified As Financing Activities", "negatedLabel": "Payment for lease liabilities", "negatedTerseLabel": "Payments of lease liabilities" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": { "auth_ref": [ "r103" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow to acquire or redeem entity's shares." } }, "en-us": { "role": { "label": "Payments to acquire or redeem entity's shares", "negatedLabel": "Payment in relation to share repurchase" } } }, "localname": "PaymentsToAcquireOrRedeemEntitysShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputEntitysOwnEquityInstruments": { "auth_ref": [ "r144" ], "lang": { "en": { "role": { "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of the entity's own equity instruments." } }, "en-us": { "role": { "label": "Percentage of reasonably possible decrease in unobservable input" } } }, "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputEntitysOwnEquityInstruments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputEntitysOwnEquityInstruments": { "auth_ref": [ "r144" ], "lang": { "en": { "role": { "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of the entity's own equity instruments." } }, "en-us": { "role": { "label": "Percentage of reasonably possible increase in unobservable input" } } }, "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputEntitysOwnEquityInstruments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "auth_ref": [ "r181" ], "lang": { "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Percentage of voting equity interests acquired" } } }, "localname": "PercentageOfVotingEquityInterestsAcquired", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PreferenceSharesMember": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Preference shares [member]", "terseLabel": "Preference Shares" } } }, "localname": "PreferenceSharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Prepayments": { "auth_ref": [ "r20" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails": { "order": 0.0, "parentTag": "cntb_OtherReceivablesAndPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered." } }, "en-us": { "role": { "label": "Prepayments", "terseLabel": "Prepayment for CRO services", "verboseLabel": "Prepayments" } } }, "localname": "Prepayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureOtherReceivablesAndPrepaymentsScheduleOfOtherReceivablesAndPrepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Presentation of leases for lessee [abstract]" } } }, "localname": "PresentationOfLeasesForLesseeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets": { "auth_ref": [ "r225" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the disposal or maturity of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } }, "en-us": { "role": { "label": "Proceeds from disposal or maturity of available-for-sale financial assets", "terseLabel": "Proceeds from disposal of financial assets at fair value through profit or loss" } } }, "localname": "ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromExerciseOfOptions": { "auth_ref": [ "r105" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of options." } }, "en-us": { "role": { "label": "Proceeds From Exercise Of Options", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromExerciseOfOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r105" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Proceeds from issue of ordinary shares", "terseLabel": "Proceeds from issuance of ordinary shares" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfessionalFeesExpense": { "auth_ref": [ "r10" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 1.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } }, "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Professional service fees" } } }, "localname": "ProfessionalFeesExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r5", "r29", "r106", "r122", "r124", "r127", "r205", "r206", "r216", "r222" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity": { "order": 0.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Loss", "negatedLabel": "Net operating loss", "terseLabel": "Net loss", "totalLabel": "Loss", "verboseLabel": "Loss for the year" } } }, "localname": "ProfitLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit Loss [Abstract]" } } }, "localname": "ProfitLossAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ProfitLossAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit Loss Attributable To [Abstract]", "terseLabel": "Loss attributable to:" } } }, "localname": "ProfitLossAttributableToAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit Loss Attributable To Owners Of Parent", "terseLabel": "Loss attributable to owners of the Company (RMB'000)", "totalLabel": "Owners of the Company" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLossPerShareScheduleOfNetBasicLossPerShareDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r1", "r2", "r183", "r205", "r206" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit Loss Before Tax", "terseLabel": "Loss before income tax", "totalLabel": "Loss before income tax", "verboseLabel": "Loss before income tax" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCashFlowInformationSummaryOfCashUsedInOperationsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r36", "r82" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit Loss From Operating Activities", "negatedLabel": "Net operating loss", "totalLabel": "Operating loss" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureGeneralInformationReorganizationAndBasisOfPresentationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r14", "r55" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property Plant And Equipment", "periodEndLabel": "Property, plant and equipment at end of period", "periodStartLabel": "Property, plant and equipment at beginning of period", "terseLabel": "Property, plant and equipment", "totalLabel": "Total property, plant and equipment", "verboseLabel": "Net book value" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r56", "r88", "r161" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property Plant And Equipment [Member]", "terseLabel": "Property, plant and equipment [member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherNoncurrentAssetsScheduleOfOtherNoncurrentAssetsParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PurchaseOfAvailableforsaleFinancialAssets": { "auth_ref": [ "r225" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } }, "en-us": { "role": { "label": "Purchase of available-for-sale financial assets", "negatedLabel": "Purchase of financial assets at fair value through profit or loss" } } }, "localname": "PurchaseOfAvailableforsaleFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r102" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase Of Property Plant And Equipment Classified As Investing Activities", "negatedLabel": "Purchase of property, plant and equipment", "negatedTerseLabel": "Purchase of property, plant and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchasesFairValueMeasurementAssets": { "auth_ref": [ "r142" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase in the fair value measurement of assets resulting from purchases of those assets. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Purchases, fair value measurement, assets", "terseLabel": "Additions" } } }, "localname": "PurchasesFairValueMeasurementAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r148", "r149", "r151", "r175", "r196", "r217" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r148", "r149", "r151", "r175", "r196", "r217" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RawMaterialsAndConsumablesUsed": { "auth_ref": [ "r1", "r39" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 8.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]" } }, "en-us": { "role": { "label": "Raw materials and consumables used", "negatedLabel": "Raw materials and consumables used", "terseLabel": "R&D materials and consumable supplies" } } }, "localname": "RawMaterialsAndConsumablesUsed", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RecurringFairValueMeasurementMember": { "auth_ref": [ "r137" ], "lang": { "en": { "role": { "documentation": "This member stands for fair value measurements which other IFRSs require or permit in the statement of financial position at the end of each reporting period. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Recurring Fair Value Measurement [Member]", "terseLabel": "Recurring" } } }, "localname": "RecurringFairValueMeasurementMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfFinancialInstrumentsCarriedAtFairValueByLevelOfInputsToValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r94" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research And Development Expense", "negatedLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } }, "en-us": { "role": { "label": "Reserve Of Sharebased Payments [Member]", "terseLabel": "Share-Based Compensation Reserves" } } }, "localname": "ReserveOfSharebasedPaymentsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r21", "r40" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained Earnings", "terseLabel": "Accumulated losses", "totalLabel": "Total retained earnings" } } }, "localname": "RetainedEarnings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromGovernmentGrants": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]" } }, "en-us": { "role": { "label": "Government grants received" } } }, "localname": "RevenueFromGovernmentGrants", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureOtherIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r160" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Rightofuse Assets", "periodEndLabel": "Net book amount, Ending balance", "periodStartLabel": "Net book amount. Beginning balance", "terseLabel": "Right-of-use assets", "totalLabel": "Net Book value", "verboseLabel": "Land of use rights" } } }, "localname": "RightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssetsRevaluedAssetsAtCost": { "auth_ref": [ "r162" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails": { "order": 0.0, "parentTag": "ifrs-full_RightofuseAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of right-of-use assets that would have been recognised had the revalued assets been carried under the cost model. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Right-of-use assets, revalued assets, at cost", "terseLabel": "Cost", "verboseLabel": "Aggregate amount paid" } } }, "localname": "RightofuseAssetsRevaluedAssetsAtCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfAmountsRecognizedInConsolidatedBalanceSheetsAsRightofuseAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SaleOrIssueOfTreasuryShares": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Sale or issue of treasury shares", "terseLabel": "Issuance of treasury shares" } } }, "localname": "SaleOrIssueOfTreasuryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SettlementsFairValueMeasurementAssets": { "auth_ref": [ "r142" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in the fair value measurement of assets resulting from settlements. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Settlements Fair Value Measurement Assets", "negatedLabel": "Settlements" } } }, "localname": "SettlementsFairValueMeasurementAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureFairValueEstimationSummaryOfChangesInLevel3InstrumentsOfShorttermInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremium": { "auth_ref": [ "r21" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share Premium", "terseLabel": "Share premium" } } }, "localname": "SharePremium", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share Premium [Member]", "terseLabel": "Share Premium" } } }, "localname": "SharePremiumMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureShareCapitalScheduleOfShareCapitalAndSharePremiumDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r176" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Sharebased Payment Arrangements [Member]", "terseLabel": "Share-based payment arrangements [member]" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": { "auth_ref": [ "r25" ], "lang": { "en": { "role": { "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares." } }, "en-us": { "role": { "label": "Shares Reserved For Issue Under Options And Contracts For Sale Of Shares", "terseLabel": "Number of shares potentially issuable", "verboseLabel": "Shares reserved for future issuance" } } }, "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_ShorttermEmployeeBenefitsExpense": { "auth_ref": [ "r10" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails": { "order": 3.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services." } }, "en-us": { "role": { "label": "Short-term employee benefits expense", "terseLabel": "Recruitment and training", "totalLabel": "Total short-term employee benefits expense" } } }, "localname": "ShorttermEmployeeBenefitsExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureExpensesByNatureSummaryOfExpensesByNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SignificantUnobservableInputLiabilities": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } }, "en-us": { "role": { "label": "Significant Unobservable Input Liabilities", "terseLabel": "Significant unobservable input, financial instruments with preferred rights" } } }, "localname": "SignificantUnobservableInputLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Changes In Equity [Abstract]" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement Of Changes In Equity [Line Items]", "terseLabel": "Statement Of Changes In Equity [Line Items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement Of Changes In Equity [Table]", "terseLabel": "Statement Of Changes In Equity [Table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r148", "r149", "r151", "r175", "r196", "r217" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top Of Range [Member]", "terseLabel": "Top of range" } } }, "localname": "TopOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedParentheticalDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade And Other Payables [Abstract]" } } }, "localname": "TradeAndOtherPayablesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "auth_ref": [ "r22" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } }, "en-us": { "role": { "label": "Trade And Other Payables To Trade Suppliers", "terseLabel": "Trade payables", "verboseLabel": "Trade Payables" } } }, "localname": "TradeAndOtherPayablesToTradeSuppliers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasuryShares": { "auth_ref": [ "r21", "r81" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury Shares", "negatedLabel": "Treasury shares", "terseLabel": "Treasury shares" } } }, "localname": "TreasuryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasurySharesMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury Shares [Member]", "terseLabel": "Treasury Shares" } } }, "localname": "TreasurySharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedStatementsOfChangesInShareholdersDeficitequity" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r176" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types Of Sharebased Payment Arrangements [Axis]", "terseLabel": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnobservableInputsAxis": { "auth_ref": [ "r139", "r145" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Unobservable Inputs [Axis]", "terseLabel": "Unobservable inputs [axis]" } } }, "localname": "UnobservableInputsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnobservableInputsMember": { "auth_ref": [ "r139", "r145" ], "lang": { "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } }, "en-us": { "role": { "label": "Unobservable Inputs [Member]", "terseLabel": "Unobservable inputs [member]" } } }, "localname": "UnobservableInputsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureFinancialInstrumentsWithPreferredRightsKeyValuationAssumptionsUsedToDetermineFairValueOfFinancialInstrumentsWithPreferredRightsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "auth_ref": [ "r49" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Useful Life Measured As Period Of Time Property Plant And Equipment", "terseLabel": "Useful life" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r63" ], "calculation": { "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails": { "order": 0.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Wages and salaries", "terseLabel": "Wages, salaries and bonuses" } } }, "localname": "WagesAndSalaries", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEmployeeBenefitExpensesScheduleOfEmployeeBenefitExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Exercisable In Sharebased Payment Arrangement2019", "terseLabel": "Options exercisable at December 31, 2021" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r170" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options exercised in share-based payment arrangement", "terseLabel": "Weighted Average Exercise Price per Share Option, Exercised during the year" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r169" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Forfeited In Sharebased Payment Arrangement2019", "terseLabel": "Weighted Average Exercise Price per Share Option, Forfeited during the six months ended June 30, 2022" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r168" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Granted In Sharebased Payment Arrangement2019", "terseLabel": "Weighted Average Exercise Price per Share Option, Granted during the six months ended June 30, 2022", "verboseLabel": "weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureEventsAfterTheReportingPeriodAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": { "auth_ref": [ "r174" ], "lang": { "en": { "role": { "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options In Sharebased Payment Arrangement Exercised During Period At Date Of Exercise2019", "terseLabel": "Weighted average exercise price during the period" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "auth_ref": [ "r178" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Fair Value At Measurement Date Share Options Granted", "terseLabel": "Weighted average fair value of options granted during the period" } } }, "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r175" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life Of Outstanding Share Options2019", "terseLabel": "Weighted average remaining contractual life of options outstanding" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Share Price Share Options Granted2019", "terseLabel": "Grant date share price", "verboseLabel": "Fair value of share based payment on grant date" } } }, "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfKeyAssumptionsForOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r85" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted Average Shares", "terseLabel": "Weighted average number of ordinary shares outstanding" } } }, "localname": "WeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/DisclosureLossPerShareScheduleOfNetBasicLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "San Diego, California", "terseLabel": "State Income Tax in California" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.connectbiopharm.com/20220630/taxonomy/role/StatementUnauditedInterimCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24" }, "r1": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24" }, "r10": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2022-03-24" }, "r100": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24" }, "r101": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard", "URIDate": "2022-03-24" }, "r102": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2022-03-24" }, "r103": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24" }, "r104": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24" }, "r105": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24" }, "r106": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24" }, "r107": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2022-03-24" }, "r108": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24" }, "r109": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24" }, "r11": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2022-03-24" }, "r110": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24" }, "r111": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24" }, "r112": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24" }, "r113": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2022-03-24" }, "r114": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2022-03-24" }, "r115": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r116": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2022-03-24" }, "r117": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2022-03-24" }, "r118": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2022-03-24" }, "r119": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "Presentation of a statement of cash flows", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS07_g10-17__IAS07_g10-17_TI", "URIDate": "2022-03-24" }, "r12": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24" }, "r120": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24" }, "r121": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24" }, "r122": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2022-03-24" }, "r123": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2022-03-24" }, "r124": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r125": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "IG63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r126": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "2", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_2_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r127": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r128": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r129": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r13": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_51&doctype=Standard", "URIDate": "2022-03-24" }, "r130": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r131": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r132": { "Clause": "ix", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r133": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r134": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r135": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r136": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r137": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2022-03-24" }, "r138": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2022-03-24" }, "r139": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2022-03-24" }, "r14": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2022-03-24" }, "r140": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_i&doctype=Standard", "URIDate": "2022-03-24" }, "r141": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r142": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r143": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2022-03-24" }, "r144": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r145": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2022-03-24" }, "r146": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard", "URIDate": "2022-03-24" }, "r147": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "B36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r148": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r149": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2022-03-24" }, "r15": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2022-03-24" }, "r150": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS13_g91-99__IFRS13_g91-99_TI", "URIDate": "2022-03-24" }, "r151": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24" }, "r152": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r153": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24" }, "r154": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2022-03-24" }, "r155": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2022-03-24" }, "r156": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_c&doctype=Standard", "URIDate": "2022-03-24" }, "r157": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_d&doctype=Standard", "URIDate": "2022-03-24" }, "r158": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2022-03-24" }, "r159": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2022-03-24" }, "r16": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24" }, "r160": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2022-03-24" }, "r161": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24" }, "r162": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "57", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_57&doctype=Standard", "URIDate": "2022-03-24" }, "r163": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI", "URIDate": "2022-03-24" }, "r164": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI", "URIDate": "2022-03-24" }, "r165": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard", "URIDate": "2022-03-24" }, "r166": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2022-03-24" }, "r167": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r168": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r169": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r17": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24" }, "r170": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2022-03-24" }, "r171": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2022-03-24" }, "r172": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2022-03-24" }, "r173": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2022-03-24" }, "r174": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2022-03-24" }, "r175": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2022-03-24" }, "r176": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r177": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2022-03-24" }, "r178": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2022-03-24" }, "r179": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard", "URIDate": "2022-03-24" }, "r18": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard", "URIDate": "2022-03-24" }, "r180": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2022-03-24" }, "r181": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r182": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r183": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r184": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a_i&doctype=Standard", "URIDate": "2022-03-24" }, "r185": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24" }, "r186": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24" }, "r187": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24" }, "r188": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24" }, "r189": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2022-03-24" }, "r19": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24" }, "r190": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2022-03-24" }, "r191": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24" }, "r192": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2022-03-24" }, "r193": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard", "URIDate": "2022-03-24" }, "r194": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2022-03-24" }, "r195": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard", "URIDate": "2022-03-24" }, "r196": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24" }, "r197": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2022-03-24" }, "r198": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_h&doctype=Standard", "URIDate": "2022-03-24" }, "r199": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8&doctype=Standard", "URIDate": "2022-03-24" }, "r2": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24" }, "r20": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24" }, "r200": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B2", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r201": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG14&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r202": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2022-03-24" }, "r203": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2022-03-24" }, "r204": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2022-03-24" }, "r205": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24" }, "r206": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24" }, "r207": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2022-03-24" }, "r208": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2022-03-24" }, "r209": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2022-03-24" }, "r21": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24" }, "r210": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2022-03-24" }, "r211": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24" }, "r212": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24" }, "r213": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24" }, "r214": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "9", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2022-03-24" }, "r215": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Effective 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24" }, "r216": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24" }, "r217": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard", "URIDate": "2022-03-24" }, "r218": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2022-03-24" }, "r219": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2022-03-24" }, "r22": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard", "URIDate": "2022-03-24" }, "r220": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "9", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2022-03-24" }, "r221": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2022-03-24" }, "r222": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24" }, "r223": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true", "URIDate": "2022-03-24" }, "r224": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24" }, "r225": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r226": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r227": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r228": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r229": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r23": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r24": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2022-03-24" }, "r25": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_vii&doctype=Standard", "URIDate": "2022-03-24" }, "r26": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24" }, "r27": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2022-03-24" }, "r28": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24" }, "r29": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2022-03-24" }, "r3": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24" }, "r30": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2022-03-24" }, "r31": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r32": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r33": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2022-03-24" }, "r34": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2022-03-24" }, "r35": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2022-03-24" }, "r36": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard", "URIDate": "2022-03-24" }, "r37": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2022-03-24" }, "r38": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_c&doctype=Standard", "URIDate": "2022-03-24" }, "r39": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard", "URIDate": "2022-03-24" }, "r4": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2022-03-24" }, "r40": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r41": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard", "URIDate": "2022-03-24" }, "r42": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2022-03-24" }, "r43": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI", "URIDate": "2022-03-24" }, "r44": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24" }, "r45": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2022-03-24" }, "r46": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r47": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI", "URIDate": "2022-03-24" }, "r48": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24" }, "r49": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2022-03-24" }, "r5": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2022-03-24" }, "r50": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24" }, "r51": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2022-03-24" }, "r52": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r53": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2022-03-24" }, "r54": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2022-03-24" }, "r55": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24" }, "r56": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard", "URIDate": "2022-03-24" }, "r57": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2022-03-24" }, "r58": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2022-03-24" }, "r59": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS16_g73-79__IAS16_g73-79_TI", "URIDate": "2022-03-24" }, "r6": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r60": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2022-03-24" }, "r61": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138&doctype=Standard", "URIDate": "2022-03-24" }, "r62": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard", "URIDate": "2022-03-24" }, "r63": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard", "URIDate": "2022-03-24" }, "r64": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS19_g2-7__IAS19_g2-7_TI", "URIDate": "2022-03-24" }, "r65": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2022-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2022-03-24" }, "r66": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2022-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2022-03-24" }, "r67": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "20", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS20_g39-39__IAS20_g39-39_TI", "URIDate": "2022-03-24" }, "r68": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24" }, "r69": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24" }, "r7": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24" }, "r70": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24" }, "r71": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2022-03-24" }, "r72": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24" }, "r73": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24" }, "r74": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18&doctype=Standard", "URIDate": "2022-03-24" }, "r75": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard", "URIDate": "2022-03-24" }, "r76": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI", "URIDate": "2022-03-24" }, "r77": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r78": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2022-03-24" }, "r79": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_vi&doctype=Standard", "URIDate": "2022-03-24" }, "r8": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24" }, "r80": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2022-03-24" }, "r81": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24" }, "r82": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2022-03-24" }, "r83": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24" }, "r84": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard", "URIDate": "2022-03-24" }, "r85": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24" }, "r86": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI", "URIDate": "2022-03-24" }, "r87": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24" }, "r88": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24" }, "r89": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r9": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24" }, "r90": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24" }, "r91": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24" }, "r92": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24" }, "r93": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2022-03-24" }, "r94": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24" }, "r95": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2022-03-24" }, "r96": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard", "URIDate": "2022-03-24" }, "r97": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24" }, "r98": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2022-03-24" }, "r99": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard", "URIDate": "2022-03-24" } }, "version": "2.1" }